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A B S T R A C T
Background
Infantile colic is a common disorder in the first months of life, affecting somewhere between 4% and 28% of infants worldwide,
depending on geography and definitions used. Although it is self limiting and resolves by four months of age, colic is perceived by
parents as a problem that requires action. Pain-relieving agents, such as drugs, sugars and herbal remedies, have been suggested as
interventions to reduce crying episodes and severity of symptoms.
Objectives
To assess the effectiveness and safety of pain-relieving agents for reducing colic in infants younger than four months of age.
Search methods
We searched the following databases in March 2015 and again in May 2016: CENTRAL, Ovid MEDLINE, Embase and PsycINFO,
along with 11 other databases. We also searched two trial registers, four thesis repositories and the reference lists of relevant studies to
identify unpublished and ongoing studies.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs evaluating the effects of pain-relieving agents given to infants with
colic.
Data collection and analysis
We used the standard methodological procedures of The Cochrane Collaboration.
Main results
We included 18 RCTs involving 1014 infants. All studies were small and at high risk of bias, often presenting major shortcomings
across multiple design factors (e.g. selection, performance, attrition, lack of washout period).
Three studies compared simethicone with placebo, and one with Mentha piperita; four studies compared herbal agents with placebo;
two compared sucrose or glucose with placebo; five compared dicyclomine with placebo; and two compared cimetropium - one against
placebo and the other at two different dosages. One multiple-arm study compared sucrose and herbal tea versus no treatment.
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Simethicone. Comparison with placebo revealed no difference in daily hours of crying reported for simethicone at the end of treatment
in one small, low-quality study involving 27 infants. A meta-analysis of data from two cross-over studies comparing simethicone with
placebo showed no difference in the number of of infants who responded positively to treatment (risk ratio (RR) 0.95, 95% confidence
interval (CI) 0.73 to 1.23; 110 infants, low-quality evidence).
One small study (30 participants) compared simethicone with Mentha piperita and found no difference in crying duration, number of
crying episodes or number of responders.
Herbal agents. We found low-quality evidence suggesting that herbal agents reduce the duration of crying compared with placebo
(mean difference (MD) 1.33, 95% CI 0.71 to 1.96; three studies, 279 infants), with different magnitude of benefit noted across studies
(I² = 96%). We found moderate-quality evidence indicating that herbal agents increase response over placebo (RR 2.05, 95% CI 1.56
to 2.70; three studies, 277 infants).
Sucrose. One very low-quality study involving 35 infants reported that sucrose reduced hours spent crying compared with placebo
(MD 1.72, 95% CI 1.38 to 2.06).
Dicyclomine. We could consider only one of the five studies of dicyclomine (48 infants) for the primary comparison. In this study,
more of the infants given dicyclomine responded than than those given placebo (RR 2.50, 95% CI 1.17 to 5.34).
Cimetropium bromide.Data from one very low-quality study comparing cimetropium bromide with placebo showed reduced crying
duration among infants treated with cimetropium bromide (MD -30.20 minutes per crisis, 95% CI -39.51 to -20.89; 86 infants). The
same study reported that cimetropium increased the number of responders (RR 2.29, 95% CI 1.44 to 3.64).
No serious adverse events were reported for all of the agents considered, with the exception of dicyclomine, for which two of five studies
reported relevant adverse effects (longer sleep 4%, wide-eyed state 4%, drowsiness 13%).
Authors’ conclusions
At the present time, evidence of the effectiveness of pain-relieving agents for the treatment of infantile colic is sparse and prone to bias.
The few available studies included small sample sizes, and most had serious limitations. Benefits, when reported, were inconsistent.
We found no evidence to support the use of simethicone as a pain-relieving agent for infantile colic.
Available evidence shows that herbal agents, sugar, dicyclomine and cimetropium bromide cannot be recommended for infants with
colic.
Investigators must conduct RCTs using standardised measures that allow comparisons among pain-relieving agents and pooling of
results across studies. Parents, who most often provide the intervention and assess the outcome, should always be blinded.
P L A I N L A N G U A G E S U M M A R Y
Pain-relieving agents for infantile colic
Review question
Do infants who have colic during the first four months of life benefit from pain-relieving agents (substances to alleviate/prevent pain)
when compared with infants who are given no substance or a placebo (a substance that is identical to the drug but has no active
ingredient)?
Background
Infantile colic, which is a common problem in infancy, occurs in the first four months of life in otherwise healthy infants. It is
characterised by episodes of excessive crying and often leads to anxiety in parents and in doctors who work with infants.
Pain-relieving agents, such as drugs (e.g. simethicone, dicyclomine, cimetropium), herbal remedies (e.g.Matricaria recutita, Foeniculum
vulgare, Melissa officinalis) and sugar, have been proposed to reduce the symptoms associated with infantile colic, particularly the amount
of time spent crying.
Study characteristics
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We found 18 randomised controlled trials (studies in which participants were randomly assigned to one of two or more treatment
groups) involving 1014 infants with infantile colic. The evidence is current to May 2016.
Infants were eight to 16 weeks old, and males and females were equally represented. All infants had colic, defined in one of two ways.
Some studies defined it as inconsolable crying in otherwise healthy infants, lasting longer than three hours per day for more than three
days a week for longer than three weeks. Other studies defined colic as attacks of screaming and crying (usually in the afternoon, or in
the early evening) during which the infant failed to respond to any amount of comforting by adults.
Four studies explored the effects of simethicone (a drug used to reduce excess gas in the intestinal tract); four studies looked at herbal
agents (plant-derived remedies that might have relaxing properties that reduce cramps and pains in the bowel); two studies looked at
sugar; and five studies explored the effects of dicyclomine and two the effects of cimetropium bromide (drugs that relieve bowel muscle
spasms). One study compared sucrose and herbal tea in a group of infants who received no treatment for colic.
Sixteen of 18 studies compared the intervention with a placebo. Among the other two studies, one compared simethicone withMentha
piperita, and the other compared two different dosages of cimetropium.
Included studies received funding from different sources: a public institution (two studies), academic funds (one study) and private
companies (three studies). Three studies received no funding. Nine studies did not report whether the study received funding. In four
studies that reported no funds and no details about funds, private companies supplied the products (pain-relieving agents).
Key results
Available data provide no evidence that sugar, dicyclomine and cimetropium are effective interventions in the treatment of colic. Some
evidence suggests that, compared with placebo or no treatment, herbal agents may reduce crying time. However, because the quality
of these studies was very poor and the extent of the benefit observed was variable, these results should be interpreted with caution. The
same is true for sugar, dicyclomine and cimetropium, for which we judged the quality of evidence as low or very low.
Studies that tested simethicone reported no benefit from administration of this drug over placebo.
Two studies reported side effects for dicyclomine, for example, difficulty awakening, wide-eyed state and drowsiness. Studies of other
pain-relieving agents reported no side effects as a result of treatment.
Quality of the evidence
Low-quality evidence indicates that infants with colic may benefit from treatment with sugar and cimetropium, and that herbal agents
may reduce crying time.Moderate-quality evidence suggests that these agents increase the number of children experiencing improvement
in symptoms. Overall, evidence is insufficient to allow firm conclusions about the benefits and side effects of the pain-relieving agents
examined for treatment of crying due to infantile colic.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Simethicone versus placebo for infantile colic
Patient or population: infants with infant ile colic
Settings: university primary care centre (Sweden) and general paediatric pract ices (USA)
Intervention: simethicone versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Simethicone vs
placebo
Reduction in crying du-
ration
Dif ference between f i-
nal values (hours per
day of crying)
Follow-up: mean 7 days
Mean crying durat ion in
control groups was 4.
37 hours/ d
Mean crying durat ion
in intervent ion groups
was 0.13 lower (1.4
lower to 1.14 higher)
M D -0.13 (-1.40 to 1.
14)
27
(1 study)
⊕©©©
Very lowa,b
-
Responders
Number of infants who
improved af ter treat-
ment
Follow-up: mean 7 days
Study population RR 0.95
(0.73 to 1.23)
110
(2 studies)
⊕⊕©©
Lowa,c
-
591 per 1000 561 per 1000
(431 to 727)
M oderate
604 per 1000 574 per 1000
(441 to 743)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluat ion; MD: mean dif ference; RR: risk rat io
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aHigh risk of select ion, attrit ion and report ing bias.
bOnly one study with 27 infants.
cOnly two studies with 110 infants.
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B A C K G R O U N D
Infants cry for various reasons to express discomfort caused by con-
ditions ranging from benign disorders to life-threatening illness.
Heine 2006 suggested that less than 5% of distressed infants have
identifiable medical explanations for their crying. Infantile colic,
which is defined as excessive crying in the first few months of life,
is a common but poorly understood and often frustrating problem
for parents and carers, and is frequently a reason for consultation
with paediatricians and community nurses (Freedman 2009).
Description of the condition
Infantile colic represents a clinical condition with a reported inci-
dence from 4% to 28%; this wide range of occurrence seems not
to be associated with factors such as nationality and clinical criteria
(i.e. gender, socioeconomic class, type of feeding, family history
of atopy, and parental smoking) (Lucassen 2001; Lucassen 2015;
Vandenplas 2015). Infantile colic is characterised by inconsolable
crying, fussing and irritability in an otherwise healthy newborn
during the first threemonths of life. Infant crying tends to occur in
the evening and usually increases at six weeks of age, with drawing
up of the legs, tension of the body, flushing of the face, painful
bowel movements and meteorism (abdominal bloating). The di-
agnosis is clinical, and the most often cited definition is based on
the rule of three, that is, unexplained episodes of paroxysmal cry-
ing for longer than three hours per day for three days per week
for at least three weeks (Wessel 1954). Many other definitions
are available, reflecting different conditions with other risk factors
(Reijneveld 2002). Infantile colic shows a wide range of clinical
manifestations and can be graded as mild, moderate or severe, but
no consensus is known for this classification. The natural history
of infantile colic is favourable, and symptoms gradually disappear
by around three months of age.
It has been suggested that both biological components (food hy-
persensitivity/allergy and gut dysmotility) and behavioural factors
(psychological and social) may play a role in the development of
colic (Gupta 2007). It seems that some infants are predisposed to
visceral hypersensitivity and hyperalgesia in the first weeks of life.
Available evidence suggests that infantile colic might have several
independent causes, including those listed below (Savino 2007).
• Carbohydrate malabsorption, in particular, lactose
intolerance due to a relative lactase deficiency (Kanabar 2001).
• Food hypersensitivity (cow’s milk allergy; Hill 2000; Iacono
2005). Colic might represent an early manifestation of food
allergy, although results of studies investigating a link between
infant colic and atopy have been conflicting (Gupta 2007; Heine
2006; Iacono 1991). Some infants with moderate or severe
symptoms have cow’s milk-dependent colic that improves after a
few days of a hypoallergenic diet. Therefore, in bottle fed babies,
a two-to-four-week trial of extensively hydrolysed formulae has
been recommended (Fiocchi 2010; Nocerino 2015).
• Feeding disorder, that is, disorganised feeding behaviour
and lower responsiveness during feeding interaction with mother
(Miller-Loncar 2004).
• Dysmotility. Some researchers have suggested that transient
dysregulation of the nervous system during development may
cause intestinal hypermotility in infants with colic; the
predominance of the parasympathetic and the sympathetic
nervous system has also been investigated (Garrison 2000;
Lucassen 1998; Savino 2002; Weissbluth 1984).
• Gut microflora. Lehtonen 1994 first hypothesised that
infantile colic may arise from an aberrant gut microbial
composition in the first months of life that affects the intestinal
fatty acid profile. The role of peculiar intestinal lactobacilli and a
particular coliform colonisation pattern has been proposed in the
etiopathogenesis of the condition (Savino 2004; Savino 2005b;
Savino 2009). More recently, Rhoads demonstrated that gut
inflammation and an altered, less diverse fecal flora are seen in
infants with colic (Rhoads 2009).
• Psychological factors, such as personality disturbance in the
child or less than optimal parent-infant interactions (Akman
2006; Canivet 2000; Räihä 2002; Van den Berg 2009; Vik
2009).
• Possibly higher rate of night wakening and less nocturnal
sleep (Lehtonen 1994b). Data suggest that colic may be
associated with disruption and delay in maturation of the
circadian rhythm and sleep-wake organisation, both of which
resolve when colic disappears; however, the topic of effects of
colic on sleep remains controversial (Sadeh 2009).
• Recent hypotheses. Effects of hormone alterations (Savino
2006) and maternal smoking (Canivet 2008) remain to be
confirmed.
Infantile colic is a clinical entity with a wide range of presentations
and outcomes. Paediatricians should first exclude other underlying
diseases through medical examination and should prevent feeding
disorders. Then, in light of the favourable clinical course of the
condition, healthcare providers should assist parents in adopting
safe and well-tolerated strategies (Savino 2010).
Description of the intervention
Treatment approaches can be grouped into the following cate-
gories: pharmacological treatments (e.g. dicyclomine hydrochlo-
ride, cimetropium bromide, simethicone), probiotics, comple-
mentary therapies (including herbal agents and sucrose), manip-
ulative therapies (including acupuncture), dietary interventions
andparental behavioural interventions (Savino 2014). ACochrane
review has examined the effectiveness of manipulative therapies
(Dobson 2012); two other Cochrane reviews are ongoing - one
on the effectiveness of probiotics (Praveen 2014) and another on
dietary modification (Savino 2014b).
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This review examines the effectiveness and safety of the following
pain-relieving agents: pharmacological interventions (dicyclomine
hydrochloride, cimetropium bromide and simethicone) and com-
plementary therapies (herbal formulations, sucrose or glucose).
The development of visceral pain in infancy is a highly complex
process with important implications for analgesic policy and clini-
cal management. These agents are aimed at reducing gastrointesti-
nal discomfort, which has been theoretically linked with infantile
colic.
Dicyclomine hydrochloride is an anticholinergic drug with an-
tispasmodic activity that is used to relax muscles in the wall of
the gut and prevent spasms. Despite some findings of effective-
ness in infantile colic, adverse effects have been reported in about
5% of treated infants. Drowsiness, diarrhoea and constipation are
most commonly reported, but severe adverse effects, such as ap-
noea, breathing difficulties, seizures and coma, have also occurred
(Edwards 1984; Garriott 1984; Randall 1986; Williams 1984).
For this reason, use of anticholinergic drugs is now contraindi-
cated in infants before six months of age (Garrison 2000). Never-
theless, we decided to include dicyclomine in our review for com-
pleteness, that is, to perform a comprehensive systematic review
that includes all of the agents that have been used or are actually
used to treat infant colic, even if one or some of them are not yet
recommended because of their ineffectiveness or adverse events.
Cimetropium bromide is an antimuscarinic compound derivative
of belladonna with considerable penetration in the blood-brain
barrier. It shows competitive, surmountable antagonism of mus-
carine receptors of visceral smooth muscle and direct myolytic ac-
tivity (Bassotti 1987; Imbimbo 1986; Sagrada 1989; Scarpignato
1985; Schiavone 1985). Cimetropium bromide has been well tol-
erated in infants when administered at the tested dosage. The only
registered side effect is increased sleepiness that might be related
to pain resolution rather than to central nervous system effects
(Savino 2002).
In addition to conventional therapies, the anticholinergic and an-
tiadrenergic activities of some herbal formulations, such as fennel,
lemon balm and chamomile, have been proposed to relieve pain
(Savino 2005; Weizman 1993).
Simethicone silicone latex, a defoaming agent, is a pharmacological
agent that could act as a detergent to reduce the surface tension of
bubbles in the intestinal tract, in theory enabling abdominal gas
to be expelled more easily. It is safe and may reduce meteorism
(abdominal bloating; Metcalf 1994; Sethi 1988).
How the intervention might work
Potential remedies for the management of infantile colic have
shown different mechanisms of action; however, the ultimate goal
is to relieve pain.
Many years ago, researchers stated that most cases of infantile colic
could be explained by colonic hyperperistalsis and increased rectal
pressure. In particular, the early literature refers to colic as “hyper-
tonia of infancy”. Predominance of the parasympathetic as well
as the sympathetic nervous system has been investigated. Indeed,
the gastrointestinal tract contains a wide variety of hormones in-
volved in the regulation of intestinal motility (i.e. vasoactive in-
testinal peptide (VIP), gastrin, motilin (Lothe 1987), and ghre-
lin). Lothe 1990 hypothesised that motilin, whose serum levels
were increased in infants who developed colic, might play a central
role in the etiopathogenesis of the condition through its activity in
enhancing gastric emptying through increased small-bowel peri-
stalsis and decreased transit time. In another study, colicky infants
presented higher serum levels of motilin and ghrelin compared
with their healthy counterparts, suggesting that ghrelin may be
implicated in promoting abnormal hyperperistalsis (Savino 2006).
These concepts supported the hypothesis of beneficial effects de-
rived from drugs with antispasmodic effects, such as dicyclomine
hydrochloride, cimetropium bromide and some herbal formula-
tions. Dicyclomine, which relaxes muscles in the wall of the gut
and prevents spasms, has been used in the treatment of infantile
colic on the assumption that spasms of intestinal smooth muscle
cause colic symptoms (Grunseit 1977; Hwang 1985; Illingworth
1959; Weissbluth 1984). Cimetropium bromide may reduce in-
testinal sensitivity and hypermotility through its competitive an-
tagonism of muscarine receptors of the visceral smooth muscles
and by its spasmolytic activity (Bassotti 1987; Imbimbo 1986;
Sagrada 1989; Scarpignato 1985; Schiavone 1985). Fennel, lemon
balm and chamomile may be effective in the treatment of infan-
tile colic because of their anticholinergic and antiadrenergic activ-
ities. In particular, in animal models, upper gastrointestinal tran-
sit has been influenced by the oral administration of an herbal
formulation containing extracts from Matricaria recutita flowers
(chamomile), Foeniculum vulgare (fennel) and the aerial parts of
Melissa officinalis (lemon balm) (Capasso 2007).
Excessive intraintestinal air load, aerophagia and pain, which are
characteristic symptomsof colic crying,may be related to increased
production of gas in the lower bowel (Sferra 1996). Treem 1994
suggested that colicky infants produce large amounts of gas, prob-
ably as the result of colonic bacterial fermentation of malabsorbed
dietary carbohydrate, and that they are relieved of symptoms by
the passage of gas. Simethicone decreases abdominal distension
and discomfort due to excessive gas production through dispersion
of gas bubbles from the gastrointestinal tract. For this reason, it has
been studied as treatment for colicky infants, with researchers pos-
tulating that physical signs during colic episodes, such as bearing
down and passage of flatulence, suggest excessive gas (Danielsson
1985; Metcalf 1994; Sethi 1988).
Finally, oral sugar solution has proved to have analgesic and calm-
ing effects on newborns (Carbajal 1999; Skogsdal 1997).
Why it is important to do this review
Infantile colic is a frequent but poorly understood and often dis-
tressing problem for parents and carers. The favourable clinical
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course, the range of ways in which it manifests and the day-to-
day variability in crying time suggest that a well-tolerated, multi-
factorial and graded strategy should be adopted.
Two systematic reviews have focused on therapeutic interventions
for colic (Garrison 2000; Lucassen 2001), but these are now well
out-of-date. A more recent review, published in 2011, did not in-
clude herbal formulations (Hall 2012). A recent Cochrane review
examined the effectiveness of manipulative therapies (Dobson
2012); two other Cochrane reviews are ongoing - one on the ef-
fectiveness of probiotics (Praveen 2014), and another on dietary
modifications (Savino 2014; Savino 2014b). Ultimately, up-to-
date systematic reviews should seek to inform clinical guidelines
for the treatment of infants with colic.
O B J E C T I V E S
To assess the effectiveness and safety of pain-relieving agents for
reducing colic in infants younger than four months of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs.
Types of participants
Infants younger than four months of age at enrolment who had
infantile colic, as confirmed by a physician. Infantile colic is de-
fined as a prolonged period of crying for no apparent reason in an
otherwise healthy infant. For inclusion in this review, we accepted
all definitions of excessive crying, and both breast fed and bottle
fed infants were eligible.
We excluded studies of infants with crying of normal duration.
Types of interventions
We included any pain-relieving agent used for the treatment of
infant colic, that is, pharmacological interventions (dicyclomine,
cimetropium bromide, simethicone) and complementary inter-
ventions (herbal formulations, sucrose or glucose). These agents
could be compared with placebo or with no treatment. We also
included studies that compared two different agents against each
other and we performed separate analyses.
Types of outcome measures
Primary outcomes
• Reduction in crying duration (post-treatment vs baseline)*
(available data may be continuous, for example, hours per day, or
dichotomous, for example, reduction under a threshold defined
by trialists)
• Responders* (dichotomous outcome), defined as
proportions of participants who showed improvement by the end
of treatment, according to the measures used by study authors
Secondary outcomes
• Reduction in frequency of crying episodes (post-treatment
vs baseline)* (available data may be continuous, for example,
hours per day, or dichotomous, for example, reduction under a
threshold defined by trialists)
• Parental or family quality of life, including measures of
parental stress, anxiety or depression (continuous outcome)
• Sleeping time, that is, change in duration of peaceful
sleeping (post-treatment vs baseline)* (continuous outcome)
• Parental satisfaction, measured by Likert scales or on a
numerical rating scale (NRS) (continuous outcome)
• Adverse effects: constipation, vomiting, apnoea, apparent
life-threatening events (ALTEs) and lethargy* (dichotomous
outcome)
Timing of outcome assessment: We included outcomes evaluated
after completion of any treatment protocol (i.e. any period, any
number of treatments) and at later follow-up, if reported.
*We included those outcomes marked with an asterisk (*) in
Summary of findings for the main comparison, as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2008).
Search methods for identification of studies
We ran the initial searches in April 2012 with no limitations by
date, language or publication type. We updated the searches in
April 2014, and added an age filter to the strategies forCENTRAL,
Ovid MEDLINE and Embase to reduce the number of irrelevant
records.Weupdated the searchesmost recently on27March 2015,
andon16May2016.We reported details about each set of searches
in Appendix 1, and reported search strategies for each source in
Appendix 2.
Electronic searches
We searched the electronic databases listed below.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 4) in the Cochrane Library (searched
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16 May 2016), which includes the Cochrane Developmental,
Psychosocial and Learning Problems Group Specialised Register.
• MEDLINE Ovid (1946 to May week 1 2016).
• MEDLINE(R) In-Process & Other Non-Indexed Citations
Ovid (13 May 2016).
• Embase Ovid (1980 to 2016 week 20).
• PsycINFO Ovid (1806 to May week 2 2016).
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; 1937 to current).
• Science Citation Index Web of Science (SCI; 1970 to 16
May 2016).
• Social Science Citation Index Web of Science (SSCI; 1970
to 16 May 2016).
• Conference Proceedings Citation Index - Science Web of
Science (CPCI-S; 1970 to 16 May 2016).
• Conference Proceedings Citation Index - Social Sciences &
Humanities Web of Science (CPCI-SS&H; 1970 to 16 May
2016).
• Cochrane Database of Systematic Reviews (CDSR; 2016,
Issue 5) in the Cochrane Library (searched 16 May 2016).
• Database of Abstracts of Reviews of Effects (DARE; 2016,
Issue 2) in the Cochrane Library (searched 16 May 2016).
• WorldCat (limited to theses and dissertations;
www.worldcat.org; searched 17 May 2016).
• HOMEOINDEX (Virtual Health Library; bvsalud.org/en;
searched 17 May 2016).
• LILACS (Latin American and Caribbean Health Science
Information Database; Virtual Health Library;
lilacs.bvsalud.org/en; searched 16 May 2016).
• Networked Digital Library of Theses and Dissertations
(SCIRUS) (NDLTD; all available years up to 2012. Not
available via SCIRUS after 2012. Searched again via
search.ndltd.org/index.php on 17 May 2016).
• IBECS (Virtual Health Library; bvsalud.org/en; searched
17 May 2016).
• ClinicalTrials.gov (clinicaltrials.gov; searched 17 May
2016).
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; who.int/ictrp/en; searched 17
May 2016).
• TROVE (limited to Australian theses; trove.nla.gov.au;
searched to 27 March 2015).
• DART-Europe E-theses Portal (www.dart-europe.eu/basic-
search.php; searched to 27 March 2015).
Searching other resources
We evaluated bibliographies of articles identified through the elec-
tronic searches to look for additional published and unpublished
studies.
Data collection and analysis
Selection of studies
Two review authors (FS, VT) independently screened titles and
abstracts yielded by the searches, discarding irrelevant records. Re-
view authors then retrieved the full text of all potentially eligible
articles to assess them independently against the inclusion criteria.
We resolved discrepancies through discussion and,whennecessary,
by consultation with a third review author (EB). If information
was not forthcoming, or if we were unable to resolve the dispute,
we approached the Cochrane Developmental, Psychosocial and
Learning Problems Group (CDPLPG) editorial base for advice.
Data extraction and management
We developed data extraction forms a priori, as per recommenda-
tions provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a).We extracted the information listed
below.
• Methods: study design, setting, duration, recruitment
procedures, risk of bias (such as sequence generation, allocation
concealment, blinding of outcome assessors, evaluation of
success of blinding).
• Participants: source of participants, inclusion/exclusion
criteria, total number at baseline, total number at completion,
definition of ’colic’ applied, diagnostic criteria applied, age at
onset of colic, age at commencement of intervention, evaluation
of potential effects of confounding characteristics (e.g. age,
gender, breast fed or bottle fed).
• Interventions and controls: number of groups,
intervention(s) applied, frequency and duration of treatment,
total number of treatments, permitted co-interventions,
evaluation of potential therapeutic value of sham/placebo.
• Outcomes: list of outcomes assessed, definitions used,
values for mean and standard deviation (SD) at baseline and at
time points defined by the study protocol (or change from
baseline measures, if given).
• Results: measures at end of protocol, follow-up data
(including means, SDs, standard errors and confidence intervals
(CIs) for continuous data and frequencies for dichotomous
data), withdrawals, loss to follow-up.
• Other: references to other relevant studies, points to follow
up on with study authors, comments from review authors, key
conclusions of the study (of study authors), other comments
from review authors.
Two review authors (FS, VT) extracted data independently using
the data extraction form. The third review author (EB) resolved
disagreements.
We used the latest version of Review Manager (RevMan) software
(RevMan 2014).
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Assessment of risk of bias in included studies
Two review authors (FS, VT) independently evaluated each study
for risk of bias using the criteria recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b)
for the domains of random sequence generation, allocation con-
cealment, blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, selective outcome re-
porting and other potential threats to validity. For each included
study, review authors rated each domain as having low, high or
unclear risk of bias, and then compared their grading. In the case
of differently scored items, the two review authors tried to reach
agreement by discussion. If this was not possible, we discussed dis-
agreements with the rest of the team until consensus was reached.
Review authors were not blinded to the titles of journals nor to the
identities of study authors, as they are familiar with the field. We
provide in Appendix 3 a detailed description of the criteria used
to judge risk of bias for each domain.
In this context, parents often administered the intervention. Thus,
we primarily assessed the risk of bias associated with blinding of
participants and personnel on the likelihood that such blinding
was sufficient to ensure that parents had no knowledge of which
intervention the infant received. We considered blinding of par-
ticipants to be unnecessary in this population of young infants.
We considered as outcome assessors both parents and those who
interpreted the crying diaries (paediatrician, nurse).
Measures of treatment effect
Dichotomous data
For dichotomous data, we calculated effect sizes as risk ratios (RRs)
with their associated 95% CIs and probability values (P values),
when possible. When the RR did not straddle the position of null
effect, we pooled dichotomous data and calculated the number
needed to treat for an additional beneficial outcome (NNTB) and
the associated 95% CI.
Continuous data
For continuous outcomes, we presented mean differences (MDs)
in change scores or final values, according to available data, and
95% CIs. If studies used different scales to measure the same out-
come, we used the standardised mean difference (SMD) to stan-
dardise the MD to a uniform scale.
Unit of analysis issues
For each included study, we determined whether the unit of anal-
ysis was appropriate for the unit of randomisation and the design
of each study (in other words, whether the number of observations
matched the number of randomised ’units’) (Deeks 2008).
Studies with multiple treatment arms
When we found multi-arm studies, we combined results across all
eligible intervention (pain-relieving agents) arms, making single,
pair-wise comparisons, but we divided the sample size for com-
mon comparator arms proportionately across each comparison (
Higgins 2008c). This simple approach allowed the use of standard
software (including RevMan 2014) and prevented inappropriate
double-counting of individuals. When such a strategy prevented
investigation of potential sources of heterogeneity, we analysed
each pain-relieving agent separately.
Cross-over studies
In randomised cross-over studies, individuals receive each inter-
vention sequentially in random order. One problem with this de-
sign involves the risk of carry-over effect, which occurs when the
first treatment affects the second. To reduce the carry-over effect,
cross-over studies usually include a washout period, that is, a stage
after the first treatment but before the second treatment during
which time is given for the active effects of the first treatment to
wear off before the new treatment is begun. Inadequate washouts
are seen when the carry-over effect exceeds the washout period.
For this review, we considered a minimum of one day to be an
adequate washout period for cross-over studies.
We used the inverse variance method, as recommended by
Elbourne 2002, to include data from cross-over studies with an
adequate washout period. To take account of the correlation be-
tween the two study periods, we calculated the correlation co-ef-
ficient between periods for each study (Savino 2012). When the
correlation co-efficient could not be obtained, we used data from
the first period only. For continuous data, no studies reported the
SD of a paired t-test, and for binary data, only one of the included
studies with a planned washout period reported the number of
participants who responded to both treatments (Metcalf 1994).
Consequently, we decided to analyse cross-over trials as if they
were parallel-group trials. This approach, even if it is not the most
correct, is conservative, as it overestimates the variability between
study periods. Furthermore, we conducted separate meta-analyses
for both cross-over and parallel-group trials, thus avoiding the unit
of analysis error.
For cross-over studies with an inadequate washout period, we used
data from the first period only. If data from the first period were
not available, we did not incorporate these studies into the meta-
analysis.
Dealing with missing data
For missing continuous data, we estimated SDs from other avail-
able data, such as standard errors, or we imputed them using the
methods described in Higgins 2011c. We made no assumptions
about loss to follow-up, and we based our analyses on participants
who completed the trial.
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For missing dichotomous outcomes, we investigated the effects of
dropout and exclusion by conducting analyses of worst-case versus
best-case scenarios.
If we noted a discrepancy between the number randomised and
the number analysed in each treatment group, we calculated and
reported the percentage lost to follow-up for each group.
For all included studies, we analysed available data. When we ob-
served that data were missing, we recorded this on the data collec-
tion form and reported it in the ’Risk of bias’ table (beneath the
Characteristics of included studies tables), and in the Discussion
section of the review, we considered the extent to which the miss-
ing data could alter our results and conclusions.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant factors (e.g. age) across trials, interven-
tions and outcomes. We assessed methodological heterogeneity by
comparing the distribution of important trial factors (e.g. study
design, risk of bias (such as randomisation concealment, blinding
of outcome assessment), losses to follow-up).
We assessed statistical heterogeneity by examining the I² statistic
(Deeks 2008), a quantity that describes the proportion of variation
inpoint estimates that is due to variability across studies rather than
to sampling error. We interpreted the I² statistic as recommended
in the latest version of Higgins 2011c, as follows.
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: may represent considerable heterogeneity.
We also evaluated the CI for the I² statistic.
In addition, we employed aChi² test of homogeneity to determine
the strength of the evidence that heterogeneity was genuine, and
used Tau² to assess between-study variability.
Assessment of reporting biases
To minimise publication bias, we attempted to obtain the results
of unpublished studies to compare results extracted from pub-
lished journal reports with results from other sources (including
correspondence).
Data synthesis
When interventions were similar in terms of type of pain-relieving
agent, type of outcome assessed and type of colic, we grouped
these studies and synthesised their results in a meta-analysis. We
presented results for each combination of pain-relieving agent and
assessed outcome and colic type, except in studies for which no
data were provided.
Because we assumed that clinical heterogeneity was very likely to
impact the results of our review, given the wide breadth and types
of interventions included, we combined studies by using a ran-
dom-effects model, regardless of statistical evidence of heterogene-
ity for effect sizes. We calculated all overall effects by using the
inverse variance method. We converted continuous data to MD,
and if different scales were used, we first computed SMD, then
overall MD and overall SMD (Schünemann 2008). If both a con-
tinuous outcome and a dichotomous outcome were available for
a particular outcome, we included only the continuous outcome
in the primary analysis. If some studies reported an outcome as a
dichotomous measure and others used a continuous measure for
the same construct, we converted results of the former from an
odds ratio (OR) to an SMD (Deeks 2011), provided that we could
assume the underlying continuous measure had approximated a
normal or logistical distribution (otherwise, we carried out two
separate analyses).
We carried out statistical analyses by using RevMan 2014.
Summary of findings table
We summarised the evidence in ’Summary of findings’ tables
and provided summary estimates of absolute and relative effects
(see Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; and Summary of findings 4).
We included a rating (ranging from very low to high) of our con-
fidence in the estimate of effect for the overall quality of evidence
for each outcome, as assessed via the GRADE approach (Guyatt
2008; Guyatt 2013). We used an iterative, electronic correspon-
dence discussion process to reach consensus on factors that affect
confidence in the estimate of effects (including risk of bias, i.e.
design and study limitations; imprecision; indirectness (directness
in the GRADE approach includes generalisability and applicabil-
ity); inconsistency of results, i.e. heterogeneity; magnitude of ef-
fect; and issues of residual plausible confounding); and in evidence
rating.
Subgroup analysis and investigation of heterogeneity
We performed no subgroup analyses because we included too few
studies in each comparison, making subgroup analyses impossible
or non-informative.
Subgroup analyses archived for future updates of this review can
be found in Appendix 4 and in our protocol (Savino 2012).
Sensitivity analysis
We conducted sensitivity analyses to determine whether findings
were sensitive to restriction of analyses to studies judged to be at
low risk of bias for blinded assessment of the primary outcome.
When sensitivity analyses confirmed results of the main analysis,
we regarded results of the review with a higher degree of certainty.
We did not conduct planned sensitivity analyses to investigate the
impact ofmissing data on results because the percentage ofmissing
data was low in all included studies (ranging from 0% to 16.7%;
11Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
see Table 1). These sensitivity analyses, which have been archived
for future updates of this review, can be found in Appendix 4 and
in our protocol (Savino 2012).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; and Characteristics of ongoing studies.
Results of the search
The electronic search identified 1306 records up to 16 March
2016.
After removing duplicates, we identified 1060 potentially relevant
records. Two review authors (FS, VT) screened titles and abstracts
for relevance and excluded 1032 records. We retrieved full-text re-
ports of the remaining 28 records and assessed these against the in-
clusion/exclusion criteria (Criteria for considering studies for this
review).We excluded nine studies (see Excluded studies) and iden-
tified one ongoing study (see Characteristics of ongoing studies),
leaving 18 eligible studies that contributed to 19 comparisons (see
Characteristics of included studies). A third independent review
author (EB) screened reports of studies in which FS collaborated
as a study author.
See Figure 1 for the study flow diagram.
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Figure 1. Study flow diagram.
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Included studies
Eighteen studies involving 1014 infants met the inclusion criteria
for this review (see Characteristics of included studies). The se-
lected studies were conducted between 1959 (Illingworth 1959)
and 2013 (Montaseri 2013).
Study design
All studies were RCTs.We found no quasi-RCTs. Ten of 18 studies
(56%) were cross-over trials (Akçam 2006; Alves 2012; Blomquist
1983;Danielsson 1985;Grunseit 1977;Hwang 1985; Illingworth
1959; Markestad 1997; Metcalf 1994; Sethi 1988).
Setting
Eleven studies were conducted in Europe (Akçam 2006; Arikan
2008; Blomquist 1983; Danielsson 1985;Gomirato 1989;Hwang
1985; Illingworth 1959; Markestad 1997; Savino 2002; Savino
2005; Sethi 1988), three in America (Alves 2012; Metcalf 1994;
Weissbluth 1984), two in Asia (Montaseri 2013; Weizman 1993),
one inRussia (Alexandrovich 2003) and one inAustralia (Grunseit
1977).
Most of the studies were performed in children’s hospitals (
Alexandrovich 2003; Alves 2012; Arikan 2008; Gomirato 1989;
Illingworth 1959; Markestad 1997; Savino 2002; Savino 2005,
Weissbluth 1984), four in primary care clinics (Grunseit 1977;
Hwang 1985; Montaseri 2013; Weizman 1993) and the remain-
ing five in general practitioner and paediatric outpatient clinics
(Akçam 2006; Blomquist 1983; Danielsson 1985; Metcalf 1994;
Sethi 1988).
Participants
The number of participants randomised to intervention and con-
trol groups ranged from 18 (Blomquist 1983) to 175 (Akçam
2006).
Participant age ranged from about one week (Sethi 1988) to 16
weeks (Montaseri 2013). Two studies did not provide the ages of
enrolled infants (Metcalf 1994; Savino 2002).
Definition of colic
The definition of infant colic most commonly used within
the broader literature is that given by Wessel 1954: “incon-
solable crying for more than three hours per day for more than
three days a week for more than three weeks”. A total of 13
of the 18 included studies used this definition (Akçam 2006;
Alexandrovich 2003; Alves 2012; Arikan 2008; Gomirato 1989;
Hwang 1985; Markestad 1997; Metcalf 1994; Montaseri 2013;
Savino 2002; Savino 2005; Weissbluth 1984; Weizman 1993),
and some used minor modifications or more specific definitions
(Akçam 2006; Alexandrovich 2003; Hwang 1985; Markestad
1997; Metcalf 1994; Montaseri 2013). Grunseit 1977 defined in-
fant colic as “post-prandial attacks of screaming and crying, un-
abated by maternal comforting, vomiting and sleep disturbance”,
and Illingworth 1959 reported that “the diagnosis was based on
rhythmical attacks of screaming in the evenings in well, thriving
babies who were gaining not less than seven oz per week during
the period of observation, screaming unabated when the baby was
picked up”. The three remaining studies provided no definition
of infant colic (Blomquist 1983; Danielsson 1985; Sethi 1988).
Pain-relieving agents
Pain-relieving agents varied across studies.
• Simethicone was used in four studies (Alves 2012;
Danielsson 1985; Metcalf 1994; Sethi 1988).
• Herbal formulations were used in four studies
(Alexandrovich 2003; Montaseri 2013; Savino 2005; Weizman
1993).
• Sucrose or glucose was used in three studies (Akçam 2006;
Arikan 2008; Markestad 1997).
• Dicyclomine was used in five studies (Blomquist 1983;
Grunseit 1977; Hwang 1985; Illingworth 1959; Weissbluth
1984).
• Cimetropium bromide (a drug that is distributed only in
Italy and in Corea) was used in two studies (Gomirato 1989;
Savino 2002).
• Herbal tea was used in one study (Arikan 2008).
Control conditions
In all but three studies, the control arm was given placebo.
Gomirato 1989 evaluated two different dosages of cimetropium
bromide (1.2 mg/kg vs 2.0 mg/kg); Arikan 2008 compared su-
crose or herbal tea versus no treatment; and Alves 2012 compared
simethicone medication against Mentha piperita.
Duration and frequency of treatments
Treatment schedules varied among studies.
• Ten studies lasted for 14 days. Infants received the first
treatment for seven days, then crossed to the other treatment
group for the next seven days (Danielsson 1985; Gomirato 1989;
Grunseit 1977; Hwang 1985; Illingworth 1959; Markestad
1997; Metcalf 1994; Sethi 1988; Weissbluth 1984; Weizman
1993).
• Two studies administered treatment for one week (Arikan
2008; Montaseri 2013).
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• One study lasted for eight days (Akçam 2006). Infants were
administered treatment or placebo for four days, then were
transferred over to the other study treatment arm for the next
four days.
• One study delivered treatment over a three-week period:
one week before enrolment to measure crying time followed by
two weeks of treatment (Alexandrovich 2003).
• Infants enrolled in one study received Mentha piperita for
one week, then after three days of washout received simethicone
for the next seven days (Alves 2012).
• One study had a 15-day duration consisting of one week of
treatment and one day of washout, then cross-over, followed by
seven days of placebo (Blomquist 1983).
• One study provided three days of treatment (Savino 2002).
• One study lasted for 10 days: After three days of
observation, infants were treated with an herbal agent or with
placebo for a period of one week (Savino 2005).
Outcomes
Primary outcomes
All studies provided data on at least one primary outcome (e.g.
reduction in crying duration, responders).
Table 2 shows details on different definitions of responders as given
by different study authors.
Excluded studies
We excluded eight full-text articles: three because they were not
experimental studies (Barr 1999; Benjamins 2013; Koonce 2011);
two because the comparisonwas not eligible (Oggero 1994; Savino
2007); two because they were not comparative clinical studies
(Becker 1988; NCT00655083); and one because the participants
were not eligible (NCT01532518).
Ongoing studies
One trial was ongoing and compared two different dosages of
nepadutant versus placebo (NCT01258153).
Risk of bias in included studies
We have provided details of ’Risk of bias’ assessments in
Characteristics of included studies tables, Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
16Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
We deemed the method of random sequence generation to be
adequate in four studies (Alexandrovich 2003; Alves 2012;Metcalf
1994; Montaseri 2013); we rated these studies as having low risk
of bias for this domain.
Eleven studies did not report information on sequence genera-
tion; we rated these as having unclear risk of bias (Akçam 2006;
Blomquist 1983; Gomirato 1989; Grunseit 1977; Illingworth
1959; Markestad 1997; Savino 2002; Savino 2005; Sethi 1988;
Weissbluth 1984; Weizman 1993).
We judged three studies as havinghigh risk of selectionbias because
random sequence generation was not adequate (Arikan 2008;
Danielsson 1985; Hwang 1985).
Regarding allocation concealment, five studies used an indepen-
dent person to allocate participants to groups; we judged these
as having low risk of bias for this domain (Alexandrovich 2003;
Illingworth 1959; Montaseri 2013; Weissbluth 1984; Weizman
1993). All other studies provided no information on the method
used to conceal allocation to study arms; we rated these as hav-
ing unclear risk of bias (Akçam 2006; Alves 2012; Arikan 2008;
Blomquist 1983; Danielsson 1985; Gomirato 1989; Grunseit
1977;Hwang 1985;Markestad 1997;Metcalf 1994; Savino 2002;
Savino 2005; Sethi 1988).
Blinding
We considered blinding of parents as blinding of personnel be-
cause parents administered the treatment to their infants, com-
pleted the crying diaries and described the condition of the infant.
We considered parents who completed the crying diaries, as well
as those responsible for interpreting the crying diaries (in these
situations, usually nurse or paediatrician), as outcome assessors.
Five studies provided no information on blinding of parents; we
rated these studies as having unclear risk of performance and
detection bias (Blomquist 1983; Gomirato 1989; Metcalf 1994;
Montaseri 2013; Sethi 1988).
One study did not blind parents owing to the nature of the treat-
ments compared (one of four treatment groups received massage)
(Arikan 2008). We considered this study to be at high risk of per-
formance and detection bias.
All other studies blinded parents to the treatment administered
to their infant; we considered these studies to have low risk for
performance and detection bias.
Incomplete outcome data
We judged six studies as having high risk of attrition bias
(Akçam 2006; Danielsson 1985; Grunseit 1977; Illingworth
1959; Montaseri 2013; Savino 2002).
The articles for three studies provided insufficient details on the
numbers of participants randomised and analysed; we judged these
studies to have unclear risk of attrition bias (Gomirato 1989;
Hwang 1985; Metcalf 1994).
We judged all other studies as having low risk of attrition bias be-
cause study authors reported no withdrawals, or because dropouts
were few, dropouts were balanced between groups and reasons for
dropout were reported.
Selective reporting
Three studies did not clearly specify the outcomes in the Methods
section (Alexandrovich 2003; Gomirato 1989; Grunseit 1977);
we judged these studies as having unclear risk of reporting bias.
We judged 10 studies to have high risk of bias because study au-
thors did not report the results for all outcomes mentioned in the
Methods (Arikan 2008), or, for cross-over studies, they did not
report results separately for the first study period and the end of
the study (Akçam 2006; Alves 2012; Blomquist 1983; Danielsson
1985; Hwang 1985; Illingworth 1959; Markestad 1997; Metcalf
1994; Sethi 1988).
We considered all other studies to have low risk of reporting bias.
Other potential sources of bias
We judged four cross-over studies as having high risk of other
bias because investigators planned no washout period (Akçam
2006; Blomquist 1983;Grunseit 1977; Sethi 1988); and one study
with a parallel-group design as having high risk of bias because of
imbalance in relevant characteristics at baseline (Arikan 2008).
We judged three cross-over studies as having unclear risk of
other bias because study authors provided no information about
the washout period (Hwang 1985; Illingworth 1959; Markestad
1997); one parallel-group study as having unclear risk of other
bias because baseline differences between participants could not
be excluded, as no such details were reported (Gomirato 1989);
and all other studies as having low risk of bias in this domain.
Effects of interventions
See:Summaryof findings for themain comparison Simethicone
versus placebo for infantile colic; Summary of findings 2Herbal
agents versus placebo for infantile colic; Summary of findings 3
Sugar versus placebo for infantile colic; Summary of findings 4
Cimetropium bromide versus placebo for infantile colic
Below, we present results grouped by pain-relieving agent and out-
come. We excluded from the meta-analyses six cross-over stud-
ies that provided no information about the washout period and
did not report first period data (Akçam 2006; Blomquist 1983;
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Hwang 1985; Illingworth 1959; Markestad 1997; Sethi 1988).
We provide a narrative description of these studies.
Comparison 1. Simethicone versus placebo
Three cross-over studies with 136 infants were available for this
comparison (Danielsson 1985; Metcalf 1994; Sethi 1988).
Primary outcomes
Reduction in crying duration
One study with 27 infants assessed the efficacy of simethicone
for crying duration (Danielsson 1985) and reported final crying
values only (i.e. without change scores).
Simethicone did not differ significantly from placebo as regards
daily crying duration (daily hours of difference: MD -0.13, 95%
CI -1.40 to 1.14; very low-quality evidence; Analysis 1.1).
Responders
Two cross-over studies involving 110 infants analysed the number
of infants who responded positively to treatment (Danielsson
1985; Metcalf 1994). Infants treated with simethicone did not
have a significantly higher probability of responding to this agent
than those treated with placebo (RR 0.95, 95% CI 0.73 to 1.23;
tau² = 0.01, I² = 19%; low-quality evidence; Analysis 1.2; Figure
4).
Figure 4. Forest plot of comparison: 1 Simethicone versus placebo, outcome: 1.2 Responders.
Secondary outcomes
Reduction in frequency of crying episodes
Sethi 1988 performed a cross-over study without a washout pe-
riod. Study authors reported a significant difference between active
treatment and placebo in favour of simethicone after four days of
treatment (P < 0.05). As stated above, study authors did not report
results by treatment period and arm, but stated that the order of
administration did not affect the results of treatment or placebo.
Parental or family quality of life, Sleeping time, parental sat-
isfaction,
No studies assessed these outcomes.
Adverse effects
One study (Sethi 1988) involving 26 infants reported no adverse
effects. The other two studies provided no data on adverse effects.
Comparison 2. Herbal agents versus placebo or no
intervention
We included in this comparison five parallel-group studies with
397 infants (Alexandrovich 2003; Arikan 2008; Montaseri 2013;
Savino 2005; Weizman 1993).
Primary outcomes
Reduction in crying duration
Alexandrovich 2003, Arikan2008 andSavino 2005 assessed crying
duration. Montaseri 2013 also reported data for crying duration
but reported the frequency of infants crying for less than one
hour, between one and three hours and longer than three hours.
Consequently, we were not able to include these data in the meta-
analysis.
For Analysis 2.1, we derived the correlation co-efficient from
Arikan 2008 and used it to calculate the SD of the mean reduc-
tion for Alexandrovich 2003 and Savino 2005, as suggested in the
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CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011c). From this analysis (Analysis 2.1; Figure 5), we obtained an
overall estimate, which favoured herbal formulations over placebo
(MD 1.33, 95% CI 0.71 to 1.96; tau² = 0.29, I² = 96%; 279
infants; low-quality evidence), indicating a significant difference
in crying of more than one hour each day (P < 0.0001).
Figure 5. Forest plot of comparison: 2 Herbal agents versus placebo, outcome: 2.1 Reduction in crying
duration.
Although the studies included in this analysis reported a statisti-
cally significant result in favour of herbal agents, the magnitude of
the benefit differed across studies (tau² = 0.29, I² = 96%), probably
because of the heterogeneity of the included population. In fact,
these trials included children with high variability in the duration
of crying at baseline (e.g. Alexandrovich 2003: 1.89 ± 0.25; Savino
2005: 3.33 ± 0.29 hours/d; Arikan 2008: 4.86 ± 1.43 hours/d).
We could not exclude the risk of selection bias from two studies
(Arikan 2008; Savino 2005), and we found that the risk of per-
formance, detection and reporting bias was high in Arikan 2008.
Sensitivity analysis
When we restricted the analysis to studies in which parents were
blinded (Alexandrovich 2003; Savino 2005), results remained sta-
tistically significant and favoured herbal agents (MD 1.09, 95%
CI 0.11 to 2.08; tau² = 0.50, I = 98%²; 209 infants; Analysis 2.2).
Responders
Results of a meta-analysis of the three studies reporting on respon-
ders to treatment (Alexandrovich 2003; Savino 2005; Weizman
1993) suggest benefit for herbal agents over placebo (RR 2.05,
95% CI 1.56 to 2.70; 277 infants; moderate-quality evidence;
Analysis 2.3; Figure 6).Heterogeneity among studies was low (tau²
= 0.01, I² = 13%), but we cannot rule out selection bias due to
insufficient information from Savino 2005 and Weizman 1993.
Figure 6. Forest plot of comparison: 2 Herbal agents versus placebo, outcome: 2.2 Responders.
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Secondary outcomes
Reduction in frequency of crying episodes
Only Montaseri 2013 reported the frequency of crying episodes,
but reported frequency of attacks of a particular duration: less
than one hour, between one and three hours and longer than three
hours. Study authors reported a statistically significant difference
between the two treatment arms in favour ofFumaria extract (P <
0.05); the frequency of episodes longer than one hour seemed to
be reduced in the treatment arm.
Parental or family quality of life, sleeping time, parental sat-
isfaction
No studies assessed these outcomes.
Adverse effects
Two studies reported data on adverse effects: Alexandrovich 2003
found no adverse effects. Savino 2005 reported the following ad-
verse effects among participants who received herbal agents: vom-
iting (n = 8), sleepiness (n = 2), constipation (n = 4), inappetence
(n = 1) and cutaneous reactions (n = 1) (see Table 3), and the
following adverse effects among those given placebo: vomiting (n
= 2), sleepiness (n = 1), restlessness (n = 1), inappetence (n = 3)
and constipation (n = 5).
Comparison 3. Sugar versus placebo or no
intervention
Three studies addressed this comparison (Akçam 2006; Arikan
2008; Markestad 1997). Two studies involving 50 infants used a
cross-over design in comparing sucrose or glucose solution with
placebo (Akçam2006;Markestad 1997), whereasArikan 2008 (70
infants) used a parallel-group design to compare sucrose solution
with no intervention control. Data from the two cross-over trials
provided no information about the washout period and so could
not be pooled in any meta-analysis.
Primary outcomes
Reduction in crying duration
Only Arikan 2008 reported results in terms of crying duration.
Compared with no treatment, sugar (i.e. glucose; 30%) reduced
crying duration by more than one hour (MD 1.72 hours/d, 95%
CI 1.38 to 2.06; 70 infants; very low-quality evidence; Analysis
3.1). This difference is of large magnitude, but we could not ex-
clude selection, performance, detection and reporting bias.
Responders
Akçam 2006 reportedmoderate improvement for six of 25 infants
(24%) in the glucose group compared with three of 25 (12%) in
the placebo group. Investigators reported marked improvement
for five of 25 (20%) infants in the glucose group compared with
one of 25 (4%) in the placebo group.
In Markestad 1997, 12 of 19 (63%) infants experienced an ame-
liorating effect on crying when treated with sucrose, and relapse
when treated with placebo. One infant did not improve with ei-
ther solution, and one responded better when given placebo (1/
19; 5%). For five infants, it was not possible to determine spe-
cific effects because relapse did not occur when the solution was
changed.
Secondary outcomes
No studies of sugar for infantile colic assessed its impact on fre-
quency of crying episodes, parental or family quality of life, sleep-
ing time of infants, and parental satisfaction.
Adverse effects
Only Akçam 2006 reported information on adverse effects, specif-
ically stating that no adverse effects were registered. See Table 3.
Comparison 4. Dicyclomine versus placebo
Five studies addressed this comparison. Four used a cross-over de-
sign (Blomquist 1983; Grunseit 1977; Hwang 1985; Illingworth
1959) and included 89 infants; one used a parallel-group design
and included 48 infants (Weissbluth 1984). We could not pool
data from cross-over trials because they failed to provide informa-
tion on the washout period and did not reveal first period data
by treatment arm (Blomquist 1983; Hwang 1985; Illingworth
1959), or because they presented data in a way that was not useful
(Grunseit 1977).
Primary outcomes
Reduction in crying duration
Only Hwang 1985 analysed the efficacy of dicyclomine in terms
of crying duration. This cross-over study (N = 30) provided no
information about the washout period and did not report data for
the first and second treatment periods separately. Mean hours of
crying per day were reported as 3.3 (SD 3.0) during dicyclomine
treatment and 4.3 (SD 3.9) during placebo treatment.
Responders
One parallel-group study involving 48 infants (Weissbluth 1984)
reported a significant result in favour of dicyclomine (RR 2.50,
95% CI 1.17 to 5.34; Analysis 4.1). However, we could not rule
out the risk of selection bias.
Grunseit 1977 reported a total score for symptom improvement
(crying, vomiting and sleep disturbance) by treatment arm and
by study period, but did not report the frequency with which in-
fants showed improvement or worsening of their initial condition.
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Study authors stated that their analysis suggests that dicyclomine
significantly reduced the frequency of pooled symptoms compared
with placebo (P < 0.025).
Blomquist 1983 reported that in 12 (of 18) cases, investigators
rated the solution with dicyclomine hydrochloride as having the
best effect. In four of these cases, they rated the solutions as having
an equal effect, and in two cases, they rated the solution without
dicyclomine hydrochloride as having the best effect.
Hwang 1985 reported that 25 infants improved when receiving
dicyclomine, and 17 when receiving placebo (P < 0.05).
Illingworth 1959 reported that four (of 16) infants receiving
placebo and 12 (of 20) receiving dicyclomine achieved a score of
plus three (i.e. showed improvement).
Secondary outcomes
No studies assessed the secondary outcomes of reduction in fre-
quency of crying episodes, parental or family quality of life and
parental satisfaction.
Sleeping time
Hwang 1985 provided data on sleeping time but provided no
information about a washout period in this cross-over study.
Time spent sleeping was 13.3 hours (SD 3.6) with placebo ad-
ministration and 13.8 hours (SD 3.7) with administration of di-
cyclomine.
Adverse effects
Two of five studies that compared dicyclomine versus placebo re-
ported significant adverse effects (longer sleep 4%, wide-eyed state
4%, drowsy 13%; in the placebo group, only one case of drowsiness
(2%) was reported; see Table 3) (Hwang 1985; Weissbluth 1984).
Grunseit 1977 reported side effects for three babies: One mother
reported loose motions during the last days of dicyclomine, one
reported constipation in both periods and one reported constipa-
tion during dicyclomine only.
Comparison 5. Cimetropium bromide versus placebo
Only one parallel-group study involving 86 infants examined this
comparison (Savino 2002).
Primary outcomes
Reduction in crying duration
This study found a significant, clinically relevant difference in cry-
ing duration of -30.20 minutes per crisis (95% CI -39.51 to -
20.89; very low-quality evidence) and was at low risk for perfor-
mance, detection and reporting bias, but we could not rule out
risks of selection and attrition bias.
Responders
This study found a significant result favouring cimetropium bro-
mide (RR 2.29, 95% CI 1.44 to 3.64; very low-quality evidence),
suggesting that infants treated with cimetropium bromide are
twice as likely to experience improvement in their symptoms.
Secondary outcomes
Reduction in frequency of crying episodes
This study found no significant difference between the two arms
in frequency of daily colic episodes (MD -0.40, 95% CI -1.50 to
0.70; 86 infants; Analysis 5.3).
Parental or family quality of life, sleeping time, parental sat-
isfaction
This study did not assess these outcomes.
Adverse effects
This study reported 23 adverse events in the cimetropiumbromide
arm and 19 in the placebo arm. In the cimetropium bromide
arm, study authors reported meteorism (n = 8), vomiting (n = 1),
sleepiness (n = 7), inappetence (n = 1), cutaneous reactions (n =
3) and constipation (n = 3); in the placebo arm, they reported
meteorism (n = 12), sleepiness (n = 1), restlessness (n = 1) and
constipation (n = 5). See Table 3 for details.
Comparison 6. Cimetropium bromide 1.2 mg/kg
versus cimetropium bromide 2.0 mg/kg
We included in this comparisonone parallel-group study involving
40 infants (Gomirato 1989).
Primary outcomes
Reduction in crying duration
Gomirato 1989 reported the duration of the longest daily crying
episode, providing only baseline and final values but no change
scores. Even though this was a randomised, parallel-arm trial, we
could not consider the final values because the two groups of in-
fants differed at baseline. Study authors reported that crying du-
ration decreased from 99 minutes (SD 10 minutes) to 28 minutes
(SDnineminutes) after one week of treatment, and to fiveminutes
(SD three minutes) after two weeks of treatment with the lower
dose; and from 121 minutes (SD 11 minutes) to 55 minutes (SD
seven minutes) after one week of treatment, and to 15 minutes
(SD nine minutes) after two weeks of treatment with the higher
dose. Study authors concluded that differences between the two
schedules for this parameter were not statistically significant.
Responders
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This study reported percentages of infants with excellent, good,
moderate and poor improvement by treatment group. They de-
tected no differences between arms regarding the percentage of
infants with excellent or good improvement in symptoms (85%
of cases in both arms).
Secondary outcomes
Reduction in frequency of crying episodes
This study reported the frequency of crying episodes before and
after treatment. As baseline values were similar between the two
arms in terms of crying episodes, we considered the final value
difference between the two dosages of cimetropium bromide. The
difference between final values (MD -0.50, 95% CI -0.68 to -
0.32; Analysis 6.1) in episodes of crying per day favoured 1.2 mg/
kg over 2.0 mg/kg.
Parental or family quality of life, sleeping time, parental sat-
isfaction
This study did not assess these outcomes.
Adverse effects
Four patients (10%) in the higher dosage arm had constipation,
and those in the lower dosage arm reported no adverse events (see
Table 3).
Comparison 7. Simethicone versus herbal agents
(Mentha piperita)
We included in this comparison one cross-over study involving 30
infants (Alves 2012).
Primary outcomes
Reduction in crying duration
We found no significant differences between simethicone and
Mentha piperita (MD -0.01, 95% CI -0.11 to 0.09; Analysis 7.1).
Responders
We found no significant differences between simethicone and
Mentha piperita (RR 1.08, 95% CI 0.59 to 1.97; Analysis 7.2).
Secondary outcomes
Reduction in frequency of crying episodes
We found no significant differences between simethicone and
Mentha piperita (MD -0.20, 95% CI -0.48 to 0.08; Analysis 7.3);
the difference between simethicone and Mentha piperita was less
than one episode of crying per day.
Parental or family quality of life, sleeping time, parental sat-
isfaction
This study did not assess these outcomes.
Adverse effects
Researchers reported no adverse effects.
Comparison 8. Sugar versus herbal agents
Arikan 2008 used a parallel-group design (N = 70) and included
three groups that were eligible for our review (sugar, herbal agents
and no-treatment).
Primary outcomes
Reduction in crying duration
This study found no significant differences between herbal agents
(herbal tea) and sugar (i.e. glucose; 30%) in reducing crying du-
ration (MD -0.10 hours/d, 95% CI -0.55 to 0.35; 70 infants;
Analysis 8.1 ).
Responders
This study did not assess this outcome for this comparison.
Secondary outcomes
This study provided no data relevant to our secondary outcomes
of reduction in frequency of crying episodes, parental or family
quality of life, sleeping time, or parental satisfaction and no infor-
mation on adverse events.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Herbal agents versus placebo for infantile colic
Patient or population: pat ients with infant ile colic
Settings: mult i-speciality clinics (Russia); university hospitals (Turkey, Italy); primary community-based clinics (Israel)
Intervention: herbal agents versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Herbal agents vs
placebo
Reduction in crying du-
ration
Dif ference before and
af ter treatment (hours
per day of crying)
Follow-up: mean 7 days
Mean reduct ion in cry-
ing durat ion in control
groups was 0.22 hours/
d.
Mean reduct ion in cry-
ing durat ion in inter-
vent ion groups was 1.
33 higher (0.71 to 1.96
higher).
M D 1.33 (0.71 to 1.96) 279
(3 studies)
⊕⊕©©
Lowa,b
-
Responders
Number of infants who
improved af ter treat-
ment
Follow-up: mean 7 days
Study population RR 2.05
(1.56 to 2.7)
277
(3 studies)
⊕⊕⊕©
M oderatec
-
326 per 1000 669 per 1000
(509 to 881)
M oderate
257 per 1000 527 per 1000
(401 to 694)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluat ion; MD: mean dif ference; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aOne study with high risk of select ion, performance, detect ion, report ing and other bias.
bVery high heterogeneity (96%).
cTwo studies with unclear risk of select ion bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2
4
P
a
in
-re
lie
v
in
g
a
g
e
n
ts
fo
r
in
fa
n
tile
c
o
lic
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Sugar versus placebo for infantile colic
Patient or population: infants with infant ile colic
Settings: university hospital (Turkey)
Intervention: sugar versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Sugar vs placebo
Reduction in crying du-
ration
Dif ference before and
af ter treatment (hours
per day of crying)
Follow-up: mean 7 days
Mean reduct ion in cry-
ing durat ion in control
groups was 0.09 hours/
d of crying.
Mean reduct ion in cry-
ing durat ion in inter-
vent ion groups was 1.
72 higher (1.38 to 2.06
higher).
M D 1.72 (1.38 to 2.06) 70
(1 study)
⊕©©©
Very lowa,b
-
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluat ion; MD: mean dif ference
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aHigh risk of select ion, performance, detect ion, report ing and other bias.
bOnly one study with 70 infants.
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Cimetropium bromide versus placebo for infantile colic
Patient or population: infants with infant ile colic
Settings: university hospital (Italy)
Intervention: cimetropium bromide versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Cimetropium bromide
vsplacebo
Reduction in crying du-
ration
Dif ference between f i-
nal values (minutes per
crisis of crying)
Follow-up: mean 3 days
Mean reduct ion in cry-
ing durat ion in control
groups was 47.5 min-
utes per crisis of crying
Mean reduct ion in cry-
ing durat ion in interven-
t ion groups was 30.2
lower (39.51 to 20.89
lower)
M D -30.20 (-39.51 to -
20.89)
86
(1 study)
⊕©©©
Very lowa,b
-
Responders
Number of infants who
improved af ter treat-
ment
Follow-up: mean 3 days
Study population RR 2.29
(1.44 to 3.64)
86
(1 study)
⊕©©©
Very lowa,b
-
326 per 1000 746 per 1000
(469 to 1000)
M oderate
326 per 1000 747 per 1000
(469 to 1000)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluat ion; MD: mean dif ference; RR: risk rat io
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aOnly one study with 86 infants.
bHigh risk of attrit ion bias.
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D I S C U S S I O N
Summary of main results
This review included 18 studies enrolling a total of more than
one thousand infants, and evaluated the effects of several pain-
relieving agents (i.e. simethicone, herbal remedy, sugar, dicy-
clomine, cimetropium bromide) in the treatment of infant colic.
Researchers provided no evidence of beneficial effects on crying
duration or on responders with simethicone. Herbal agents (i.e.
extract of Matricaria recutita, Foeniculum vulgare and Melissa of-
ficinalis; fennel seed emulsion; Fumaria extract; and herbal tea
preparation) were associated with reductions in crying duration
compared with placebo or no treatment, and with improvement
in symptoms, compared with placebo. However, the quality of
the evidence is low or moderate. Researchers reported some side
effects in relation to herbal agents, such as constipation, vomiting
and inappetence, which, again, limits our confidence in their use.
All studies that compared sucrose, glucose, dicyclomine and
cimetropium bromide versus placebo found evidence of low or
very low quality favouring the active intervention, with limited
sample sizes; however, on average, infants treated with the active
agent were more likely than those treated with placebo to respond
to treatment.We had expected to see half of these studies reporting
results in the opposite direction. Only two studies on dicyclomine,
a medicine that is well known to cause adverse events, reported
adverse events such as longer sleep, wide-eyed state and drowsiness
in a small percentage of infants. Only one study on sugar reported
specifically that no adverse effects were registered.
The study on cimetopium reported a total of 23 adverse events in
the cimetropium bromide arm and a total of 19 adverse events in
the placebo arm. Meteorism and constipation were slightly more
common in the placebo group, and sleepiness was more common
in the cimetropium group. Three participants in the cimetropium
group had cutaneous reactions.
None of the included studies assessed the outcomes of parental or
family quality of life, sleeping time and parental satisfaction.
See Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; and Summary of findings 4
for main comparisons.
Overall completeness and applicability of
evidence
Results of this review were derived from trials that, in general, were
poorly designed, conducted and reported.
Even though the included studies were conducted in both uni-
versity clinics and primary care hospitals, and in different coun-
tries, the applicability of retrieved evidence to clinical practice is
limited: Most trials were outdated, primary studies did not report
causes of infantile colic and heterogeneity was evident among the
colic definitions and outcome measures used. Studies most often
included small samples, and because of incomplete reporting that
made some studies almost uninformative, we were not able to pool
results of the included studies in a meta-analysis. Consequently,
the number of infants included within each comparison, includ-
ing meta-analyses, was low, ranging from 27 (for the comparison
of simethicone vs placebo, for the outcome of reduction in crying
duration) to 279 (for the comparison of herbal agents vs placebo or
no treatment for responders). Moreover, as stated above, none of
the included studies assessed parental quality of life, even though
validated questionnaires are available (Sung 2014 recently applied
such measures in a randomised controlled trial of infant colic);
thus investigators failed to recognise the negative impact that in-
fant colic can have on parents’ feelings. In fact, the persistence of
this clinical condition has the potential to damage future relation-
ships between infants and their parents (Pauli-Pott 2000). These
drawbacks also emerged during a recent systematic review of out-
come measures reported in trials of infant colic (Steutel 2014).
Given these drawbacks and the consequent low quality of the
evidence, our results should be interpreted with caution. Even if
some results look positive (for dicyclomine, herbal agents, sugar
and cimetropium bromide), the reader may conclude that the
advantages associated with these interventions are simply due to
bias. Thus, our interpretation is conservative: Based on available
evidence, we cannot recommend herbal agents, sugar, dicyclomine
and cimetropium bromide, and we believe that simethicone is no
better than placebo or Mentha.
With the exception of dicyclomine, included studies reported
no major adverse effects. For dicyclomine, two of five included
studies reported significant adverse effects over placebo (longer
sleep, wide-eyed state, drowsiness). Some case reports within the
biomedical literature have described side effects of dicyclomine
(Goldman 2004; Steinherz 2004; Walker 1988; Williams 1984).
Williams 1984 reported respiratory symptoms (such as shortness
of breath, breathing difficulty, breathlessness, respiratory collapse
and apnoeas), as well as seizures, syncope, asphyxia, pulse rate fluc-
tuations, muscular hypotonia and coma, in infants younger than
three months of age. In some cases, symptoms happened within
minutes after ingestion and lasted up to 20 to 30 minutes. Some
studies reported two cases of sudden infant death among infants
aged three months or younger who were given dicyclomine, and
described two infants as having excessively high dicyclomine blood
levels (Randall 1986; Walker 1988). Although no causal relation-
ship has been established between dicyclomine and adverse events,
dicyclomine is contraindicated in infants younger than six months
(Goldman 2004; Steinherz 2004), and its use has been banned in
this population. We agree with this position, given that no clinical
trials have been performed since 1985 (Garrison 2000; Lucassen
1998; Savino 2007b).
Quality of the evidence
Using the GRADE approach, we judged the overall quality of
evidence on the effectiveness of pain-relieving agents in infants
with colic as ranging from very low to moderate.
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Study limitations/risks of bias
Many identified studies were old, and the quality of reporting and
conduct was poor. We judged only 25% of the included studies as
having low risk of selection bias and could not consider about 30%
of studies as having low risk of performance and detection bias
because investigators did not blind parents or provided insufficient
information on blinding.We judged only 50%of studies as having
low risk of attrition bias, and we detected selective reporting of
results in about 60%.
We did not assess indirectness because population, interventions
and outcomes were those under consideration in our review, al-
though we must point out that the included studies assessed re-
sponse to treatment (i.e. improved symptoms) in different ways.
The small number of studies included for each comparison, the
variety of interventions assessed and the diversity of measures used
to assess relevant outcomes led to findings of imprecision in results
for most comparisons.
For the primary outcome ’reduction in crying duration’, results
were inconsistent for the comparison of herbal agents versus
placebo (I² = 96%). This is probably due to the different study
settings reported, although all studies showed results in favour of
herbal agents.
We could not evaluate publication bias because we included few
trials in each meta-analysis.
Overall, we judged the quality of evidence as ranging from very
low to low for simethicone, from low tomoderate for herbal agents
and very low for both sugar and cimetropium bromide.
Potential biases in the review process
We conducted comprehensive searches, including extensive
searches of the grey literature, to identify all relevant studies.
To avoid biases, two review authors (FS, VT) independently eval-
uated study eligibility, extracted data and assessed risk of bias; we
resolved disagreements by discussion with the rest of the team un-
til consensus was reached. For the two studies in which one review
author (FS) was involved (Savino 2002; Savino 2005), two other
review authors (EB, VT) who did not participate in these studies
evaluated study eligibility, extracted data and assessed risk of bias.
Our review deviated from our protocol with regards to the types
of interventions that we would include in the review and the def-
initions of outcomes used. We deemed that these changes were
necessary, so we might better describe available evidence on pain-
relieving agents for infant colic. We have described these changes
in the section Differences between protocol and review.
Finally, this review received no direct funding, although review
authors acknowledged assistance received from their associates and
institutions (please see Acknowledgements and Sources of support
sections below).
Agreements and disagreements with other
studies or reviews
We found five systematic reviews evaluating pain-relieving agents
(dicyclomine, simethicone, cimetropium bromide, herbal agents,
sugars) for the treatment of colicky infants (Cohen-Silver 2009;
Garrison 2000; Hall 2012; Lucassen 1998; Perry 2011).
Garrison 2000 and Lucassen 1998 in two systematic reviews of
treatments for infant colic reported that some evidence suggests
effectiveness of herbal tea and dicyclomine in relieving colic symp-
toms. However, these review authors suggest that use of more ob-
jective outcome measures could reduce the potential for bias.
An earlier review (Cohen-Silver 2009) reported that simethicone
was not superior to placebo in reducing symptoms of colic. Anti-
cholinergic medications, such as dicyclomine hydrochloride and
dicycloverine, have been shown to be effective in reducing peri-
staltic bowel movements. Unfortunately, these agents are associ-
atedwith several adverse effects, including loose bowelmovements,
accidental overdose of medication and the appearance of patients
as dopey, wide-eyed and excessively sleepy.
Perry 2011 performed a systematic review of all complementary
and alternative medicines and nutritional supplements for the
treatment of infantile colic. Authors of this review, which included
some of the trials considered in the present review, concluded that
they found encouraging results for fennel extract, mixed herbal
tea and sugar solutions, but stressed that these trials had major
limitations, such as small sample size, poor quality of reporting
and no mention of adverse effects.
Most recently, the systematic review Hall 2012 and the clinical
review DTB 2013 stated that review authors found poor scien-
tific evidence to support the use of simethicone, dicyclomine hy-
drochloride and cimetropium bromide. Furthermore, severe ad-
verse effects of dicyclomine hydrochloride, including respiratory
distress and seizures, have led to withdrawal of its licence for use
in infants younger than six months (Roberts 2004).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We have concluded that:
• no robust conclusions can be drawn on the effectiveness of
pain-relieving agents for the treatment of infant colic because
evidence is sparse and is prone to bias; currently only a few
studies with small sample sizes, most of them now old and with
serious limitations, are available;
• simethicone is not effective in reducing crying time or
improving symptoms when compared with placebo, which
means that no evidence suggests it is suitable for use as a pain-
relieving agent; and
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• compared with placebo, herbal agents, sugar, dicyclomine
and cimetropium bromide may be beneficial in reducing crying
time or relieving other symptoms of colic, but the quality of
evidence is low or very low. Moreover, results for dicyclomine,
sugar and cimetropium bromide are based on only one study.
Also, relevant side effects have been reported for dicyclomine,
and it has been banned from the market.
Implications for research
Current evidence on the effectiveness of pain-relieving agents for
infantile colic is based on studies that generally are small and
methodologically prone to bias.
Additional randomised controlled trials are needed: Outcomes of
crying time per day, parental quality of life and sleeping time, as
well as adverse events, should be assessed by standardised measures
that allow comparison and pooling of results across studies. In
addition, parents - those who provide the intervention and assess
the outcome - should always be blinded.
In planning new clinical trials, researchers should adopt a standard
definition of infantile colic, such as the definition proposed by
the Rome Co-ordinating Committee III (Hyman 2006), which
included the following diagnostic criteria for infantile colic: all of
the following in infants from birth to four months of age: parox-
ysms of irritability, fussing or crying that start and stop without
obvious cause; episodes lasting three or more hours per day and
occurring at least three days per week for at least one week; and
no failure to thrive.
Moreover, accurate instruments to register outcomes, such as video
or audio taping and actigraphy (Martin-Martinez 2010), should
be considered. Investigators should establish a minimum set of
outcomes, assessed in all clinical trials in infants with colic, in a
standardisedmanner, and reported in the final publication (Steutel
2014). Researchers should consider family dynamics when assign-
ing a treatment plan for infants with colic, and should acknowl-
edge that evaluation of parental satisfaction is an important aspect
of treatment efficacy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akçam 2006
Methods Randomised, double-blind, cross-over, placebo-controlled trial with 2 treatments groups
Participants Sample size: 30 infants with typical infantile colic (minimum of 3 hours of crying per
day, 3 days per week for the last 3 weeks). 5 dropped out (2 for urinary infections, 1 for
otitis and 2 because of loss of contact)
Setting: recruited from public healthcare clinics, general practitioners and the paediatric
outpatient clinic at the Maternity Hospital
Sex: boys (40%)
Mean age: 9 (SD 5.9) weeks; range not reported
Mean weight: 5046 (SD 1296) grams
Mean duration of colic: 7.1 (SD 5.4) weeks
Mean crying: 3.9 (SD 0.8) hours per day
Feeding: breast fed (10 purely breast fed; 25 partially breast fed)
Birth order: not reported
Inclusion criteria:
• Complete physical examination
• Complete blood count and urine analysis performed on all infants at the
beginning of the study to exclude other possible reason for crying
Exclusion criteria: not reported
Interventions Intervention (25 infants): glucose solution (30%) prepared for intravenous usage
Placebo (25 infants): distilled water
Administration: Parents received oral and written instructions to give 1 mL of the
distributed solution by medicine dropper over 15 to 20 minutes, while holding the
infants in their arms, when the infant continued to cry after attempts of consoling by
feeding, changing the nappy or carrying had failed. Repeat visits were scheduled for the
fourth and eighth days after the first visit. Same patients used 1 drug for 4 days, and
then used other drug for another 4 days
Duration of the study: 8 days
Washout period: not planned. Same patients used 1 drug for 4 days, then used other
drug for another 4 days
Outcomes At each visit, parents described the effect of the last treatment using a 6-point scale:
0 = ’getting worse’, 1 = ’ no improvement’, 2 = ’mild improvement’, 3 = ’moderate
improvement’, 4 = ’marked improvement’, 5 = ’completely well after each dose’. Study
authors considered infants with an improvement of 2, 3 or 4 as responders
Notes Country: Turkey
Funding source: Study authors did not report whether the study received funding
Risk of bias
Bias Authors’ judgement Support for judgement
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Akçam 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: No information was reported
about the method used to generate ran-
domisation
Allocation concealment (selection bias) Unclear risk Comment: 1 bottle containing glucose so-
lution and 1 containing distilledwater were
prepared by a pharmacist, who also ar-
ranged and kept the coding and distributed
the bottles; they were arranged in num-
bered pairs, and within the pairs, glu-
cose andplacebowere randomly designated
with the letters A and B. Each infant was
randomised to a number, and to the pair
of bottles to be tried first, by 2 separate
draws through the sealed envelope tech-
nique. Not specified whether the envelopes
were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Glucose as 30% solution and
placebo as distilled water were arranged in
identical coloured glass bottles. No infor-
mation was given to parents regarding the
contents of either bottle. The study was
conducted as double-blind - only pharma-
cist knew the bottle coding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: No information was given to
parents regarding the contents of either
bottle
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: A total of 25 of 30 infants (83.
3%) completed the study. 5 infants were
excluded (2 for urinary infections, 1 for oti-
tis and 2 because of loss of contact) for rea-
sons that seemed not related to the out-
come. Not reported during which period
they dropped out
Selective reporting (reporting bias) High risk Comment: Study authors reported data
about the outcomedeclared in theMethods
section for all 25 infants who completed
the study, but they did not report results
for each treatment by study period, neither
the number of infants who improved with
both treatments
Other bias High risk Comment: Same infants used 1 drug for
4 days, then used other drug for another 4
days. Washout period was not planned
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Alexandrovich 2003
Methods Randomised, double-blind, placebo-controlled trial with 2 treatments groups
Participants Sample size: 125 infants diagnosed with colic. Infants enrolled into the study were not
tested for milk allergy, and continued their diets. 4 participants dropped out
Setting: recruited at 2 large multi-specialty clinics of Kalinin district of St Petersburg
Sex: boys (45.5%)
Mean age: 30 (SD 7) days. Range 2 to 12 weeks
Mean weight: 3868 (SD 295) grams
Mean duration of colic: not reported
Mean crying: 13.2 (SD 1.7) hours per week
Feeding: breast fed (45.5%)
Birth order: not reported
Inclusion criteria: infants were included in the study if they met the criteria offered by
Wessel et al
Exclusion criteria:
• Premature infants
• Infants with chronic or acute illness
• Infants gaining < 30 grams a day over a period of 1 week before the study
• Infants who received any medication
• Infants with an estimated cumulative crying time < 9 hours per week
Interventions Intervention (65 infants): fennel seed oil emulsion (water emulsion of 0.1% fennel seed
oil and 0.4% polysorbate-80)
Placebo (60 infants): 0.4% polysorbate in water
Administration: A pharmacist dispensed both the fennel preparation and the placebo
into quantities sufficient to last 1 week. Parents were instructed to administer aminimum
of 5 mL and a maximum of 20 mL of fennel seed oil emulsion or placebo up to 4 times
a day, orally before meals, and at the onset of colic episodes. In addition, parents were
instructed to limit consumption to about 12 mL/kg/d, which would provide about 12
mg/kg/d of fennel seed oil
Duration of the study: 7 days (+ 7 days follow-up)
Outcomes Calculated cumulative crying for a week. Relief of colic symptoms, which was defined
as decrease in cumulative crying to < 9 hours per week
Each family received a diary with instructions to enter data on a daily basis. Diaries were
completed for 21 days: 7 days before the trial, during the 7-day trial, and 7 days after
the trial
Notes Country: Russia
Funding source: This study was supported by institutional funds. The fennel seed oil
emulsion and placebo were provided by Lev Laboratories (Glencoe, IL)
Risk of bias
Bias Authors’ judgement Support for judgement
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Alexandrovich 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Comment: Randomisation was achieved
by a computer-generated number with the
use of Microsoft Excel (Microsoft, Red-
mond, WA, USA)
Allocation concealment (selection bias) Low risk Comment: A pharmacist dispensed both
the fennel preparation and placebo in
quantities sufficient to last 1 week. The
pharmacist was unaware of which parents
received the preparation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment:The fennel preparation and the
placebo appeared identical on visual exami-
nation and were bottled in plastic 6 oz (180
mL) nursing bottles by a laboratory tech-
nician. Neither the observing paediatrician
nor parents were aware of the content of
the bottles
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Neither the observing paedia-
trician nor the parents were aware of the
content of the bottles
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: A total of 121 infants com-
pleted the study (97%). 1 infant in the
treatment group was withdrawn from the
study because his parents failed to complete
the diary. Because of a relocation, 2 infants
(twins) in the treatment group were lost to
follow-up. 1 infant in the control groupwas
withdrawn from the study because of a se-
vere cold. Percentage of drop-outs < 10%
Selective reporting (reporting bias) Unclear risk Comment: Outcomes were not clearly
specified in the Methods section.
Other bias Low risk Comment: Intervention
and control groups did not differ signifi-
cantly in baseline infant characteristics. No
significant difference in cumulative crying
was noted between the 2 groups before the
start of treatment
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Alves 2012
Methods Randomised, double blind, cross-over trial
Participants Sample size: 30 infants, diagnosed with infantile colic (Wessel criteria). No withdrawals
from the study
Setting: recruited at the Instituto de Medicina Integral by Professor Bernardo Figueira,
Receife
Sex: boys (45.5%)
Mean age: 33 (SD 11) days. Range 8 to 56 days
Mean weight: 4650 (SD 415) grams
Mean duration of colic: not reported
Mean crying: 3.2 (SD 0.8) hours per day
Feeding: breast fed (100%)
Birth order: not reported
Inclusion criteria:
• Infantile colic according to the Wessel criteria
• Complete physical examination performed to exclude other possible reasons for
crying
Exclusion criteria:
• Illiterate mothers
• Living outside the metropolitan areas of Recife
• Prematurity or low birth weight (< 2500 g)
• Failure to thrive
• Gastrointestinal disorders
• Current infection
• Allergic or metabolic disease
• Receiving other treatment for colic
Interventions Intervention (30 infants): simethicone - liquid drops (2.5mg/kg body weight), daily
for a period of 7 days
Control (30 infants): Mentha piperita - liquid drops (1 drop/kg body weight) daily for
a period of 7 days
Administration: Repeated visits were scheduled for the 7th and 17th days after the first
visit. On the 7th day visit, the medication was returned to the hospital, and another pair
of medication bottles were distributed. When patients did not return to the hospital on
the 7th day, a home visit was conducted by a researcher. During visits, the infant was
clinically examined
Duration of the study: 14 days
Washout period: 3 days. After the first 7 days of the study and a period of washout for
3 days, all infants had their medication alternated and were followed for another 7 days.
During the washout period, parents were oriented to use paracetamol for colic treatment
Outcomes Primary outcomes:
• Evaluated by mother’s opinion about responses to treatment
• Number of daily episodes of colic
• Time spent crying, measured by a chronometer
Secondary outcomes:
• Number of episodes of milk regurgitation, vomiting, diarrhoea, constipation and
drowsiness
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Alves 2012 (Continued)
Notes Country: Brazil
Funding source:This study was sponsored by INFAN, Brazil. The funding sponsor had
no involvement in the design, analysis or writing process
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Allocation sequence and ran-
domisation list were computer-gener-
ated by the “randomised” programme (
randomised.com).
Allocation concealment (selection bias) Unclear risk Comment: Information reported was in-
sufficient to permit a judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Mentha piperita and sime-
thicone were identical in weight, smell,
colour, taste and package. All researchers
and parents were unaware of the treatment
administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: All researchers and parents
were unaware of the treatment adminis-
tered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:Nowithdrawals from the study
were reported.
Selective reporting (reporting bias) High risk Comment: Study authors did not report
clearly the information about time spent
crying (outcome declared as primary in
the Methods section) by treatment period
but reported colic duration by treatment.
Moreover, they did not report results on
secondary outcomes
Other bias Low risk Comment: A 3-day washout period was
planned.
Arikan 2008
Methods Randomised, controlled trial with 4 treatment groups
Participants Sample size: 175 infants. No withdrawals from the study
Setting: recruited at public healthcare clinics and Department of Pediatrics at the Yaku-
tiye Research Hospital, Atatürk University
Sex: boys (55%)
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Arikan 2008 (Continued)
Mean age: 2.15 (SD 0.7) months. Range not reported
Mean weight: 5250 (SD 1039) grams
Mean duration of colic: not reported
Mean crying: 5.14 (SD 1.59) hours/d
Feeding: breast fed (80%)
Birth order: not reported
Inclusion criteria:
• Typical infantile colic as defined by Wessel et al
• Infant from 4 to 12 weeks of age
• Born at term or preterm (gestational age 37 to 42 weeks), with birth weight
between 2.5 kg and 4 kg
• Appropriate gain in weight, length and head circumference, and normal
psychomotor development on paediatric physical examination
Exclusion criteria:
• Previous colic treatment
• Clinical evidence of gastroenterological disease
• Mother defined as having anxiety (by means of observation)
• Infant previously treated with medication that affects abdominal symptoms, such
as antibiotic or probiotic medication
Interventions Intervention 1 (35 infants): massage (chiropractic spinal manipulation). Parents were
advised to administer massage twice a day for 25 minutes during symptoms of colic.
This time period and method were used successfully in a previous study (Huhtala et al.
2000).
Intervention 2 (35 infants): sucrose solution (12%). Sucrose administered at a dose of 2
mL of 12% solution twice a day at 5 PM and 8 PM. This concentration and volume were
chosen because they had been used successfully in a previous study on pain in newborn
infants (Haourai et al. 1995).
Intervention 3 (35 infants): herbal tea (fennel tea). Herbal tea administered at a dose
of 35 mL (maximum dose of 150 mL), 3 times a day (Weizman et al. 1993).
Intervention 4 (35 infants): hydrolysed formula. In the group receiving breast feeding,
it was thought that it would be wrong to discontinue breast feeding. Therefore, only
infants fed standard formula were assigned to the group to receive hydrolysed formula
Control (35 infants): no intervention. No nursing intervention was administered to
the control group
Administration:The same paediatrician and nurse were in contact with all study parents,
each of whom was visited and trained in the scoring system. Parents were educated by
researchers about their assigned regimen. Mothers were trained in massage technique
and were given brochures with written illustrated instructions
Duration of the study: 7 days
Outcomes Crying time: Before starting the study, parents were given a structured questionnaire
about their infants’ behaviour, temperament, sleeping and eating habits and history
of colic symptoms. Parent participants were then given a 1-week diary in which to
record crying times and durations (onset of crying time, when the intervention was
administered, end of crying time, side effects observed during week of therapy). Crying
was quantified by length of crying in hours per day for 1 week before and 1 week during
the intervention
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Arikan 2008 (Continued)
Notes Country: Turkey
Funding source: Study authors received no financial support for this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Comment: Information reported on the
group receiving breast feeding was insuffi-
cient; it was thought that it would be wrong
to discontinue breast feeding. Therefore,
only infants fedwith standard formulawere
assigned to the group to receive hydrolysed
formula
Allocation concealment (selection bias) Unclear risk Comment: No information was reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Because of the design of the
study, blinding was not applied
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: No blinding was applied.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Study authors reported study
results for all randomised infants
Selective reporting (reporting bias) High risk Comment: Parents wrote a diary to record
crying duration and side effects observed
during therapy. Side effects results were not
reported
Other bias High risk Comment: Intervention groups and con-
trol group did not differ significantly in
baseline infant characteristics, except for
crying duration
Blomquist 1983
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Participants Sample size: 18 infants. No withdrawals from the study
Setting: recruited from 9 child health centres (CHCs) in Umeå and the surrounding
area
Sex: boys (44%)
Mean age: not reported (SD not reported). Range 2 to 14 weeks
Mean weight: not reported
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Blomquist 1983 (Continued)
Mean duration of colic: not reported
Mean crying: not reported
Feeding: not reported
Birth order: not reported
Inclusion criteria:
• Parents must have sought help for the child at the CHC for colic problems.
• The CHC nurse and/or CHC doctor then determined if the child’s problems
were to be considered infantile colic.
Exclusion criteria: not reported
Interventions Intervention (18 infants): dicyclomine hydrochloride 100 mg in 100 mL of solution.
As the mixture has a sweet and sour flavour, sugar and lemon lime were added
Control (18 infants): placebo. Dosage was 5 mL of the respective solution, given 20
minutes before afternoon and eveningmeals. Parents were asked to refrain from changing
the infant’s diet during treatment
Administration: After 1 week, parents returned to the CHC for follow-up, which in-
cluded a weight check. At this time, parents made an overall assessment of the treatment
week. Parents returned the first bottle and were given the new code-labelled bottle. After
an additional week, parents made a new overall assessment in connection with a new
visit to the CHC
Duration of study: 2 weeks
Washout period: no washout period planned
Outcomes The CHC distributed a diary containing data entry pages for 15 days of treatment. In
the diary, parents recorded, for each day, times of meals, colic attacks, bowel movements
and colic medications. Parents also commented on how severe they considered the child’s
colic attacks to have been during the past 24-hour period (none, mild, moderate, severe,
very severe). In addition, parents assessed during which week treatment showed the
highest efficacy
Notes Country: Sweden
Funding source: Study authors did not specify whether they received financial support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement of low risk. Order of
use between the 2 treatment alternatives
was randomly assigned
Allocation concealment (selection bias) Unclear risk Comment: No information was reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment:Two code-labelled bottles - 1 of
which contained dicyclomine hydrochlo-
ride, and the other, the solution without
dicyclomine hydrochloride - were given to
each infant
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Blomquist 1983 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment:Two code-labelled bottles - 1 of
which contained dicyclomine hydrochlo-
ride, and the other, the solution without
dicyclomine hydrochloride - were given to
each infant
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Study authors reported study
results for all randomised infants
Selective reporting (reporting bias) High risk Comment:Outcomeswere not clearly pre-
specified, and details of results were not re-
ported by study period
Other bias High risk Comment: No washout period was
planned.
Danielsson 1985
Methods Double-blind, placebo-controlled, cross-over trial
Participants Sample size: Study included 32 infants with colic: 5 infants dropped out after 2 to 7
days owing to parents’ decisions (2 taking simethicone, and 3 placebo). Data from this
study were derived from 27 infants
Setting: baby clinics near Gothenburg
Sex: boys (44%)
Mean age: 4.8 (SD not reported) weeks; range 2 to 8 weeks
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: not reported
Feeding: breast fed (all mothers, except 1, were breast feeding); received bottle supple-
ments (3 mothers gave their infants occasional bottle supplements)
Birth order: not reported
Inclusion criteria:Crying was diagnosed as infantile colic if it lasted longer than 3 hours
a day and occurred more than 3 days a week
Exclusion criteria: not specified
Interventions Intervention (27 infants): simethicone: 0.3 mL (10 drops) of simethicone solution (94
mg/mL) administered to each infant before each meal
Control (27 infants): placebo; designed to have the same taste, smell, colour and texture
as the active solution
Administration: The same assistant visited each family twice. The first treatment was
administered from day 1 to day 7; this was followed by a 3-day washout period. The
second treatment was administered from day 11 to day 17
Duration of study: 7 days of treatment, 3 days of washout and 7 days of another
treatment
Washout period: 3 days
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Danielsson 1985 (Continued)
Outcomes Parents were interviewed before and after treatment to obtain background data and to
evaluate treatment efficacy. Parents kept 24-hour records about how long their infants
had been crying or fussing, and how often their infants had eaten and passed stools
Notes Country: Sweden
Funding source: This research was supported by a grant from the First of May Flower
Annual Campaign for Children’s Health (Sweden)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Comment: It is not clearly reported
whether treatment order was assigned by
randomisation
Allocation concealment (selection bias) Unclear risk Comment: Information was insufficient to
permit a judgement.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment:Medicine bottleswere codedby
the manufacturer; placebo and tested drug
had the same smell, taste, colour and tex-
ture
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:Medicine bottleswere codedby
the manufacturer; placebo and tested drug
had the same smell, taste, colour and tex-
ture
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment:Five infants dropped out owing
to parents’ decisions (2 taking simethicone,
and 3 placebo). 15% were lost. Balanced
reasons for dropout were reported
Selective reporting (reporting bias) High risk Comment: Outcomes were not clearly re-
ported in the Methods section, and results
were not reported by study period
Other bias Low risk Comment: Three-day washout period was
planned.
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Gomirato 1989
Methods Randomised, controlled, parallel-group trial
Participants Sample size: 40 infants. Information on dropouts was not clearly reported
Setting: not reported
Sex: boys (40%)
Mean age: 4.4 (SD not reported) weeks; range not reported
Mean weight: not reported (SD not reported)
Mean duration of colic: ≥ 1 week
Mean crying: longer than 90 consecutive minutes
Feeding: not reported
Birth order: not reported
Inclusion criteria:
• Symptoms of infant colic lasting for ≥ 1 week, with crying fits lasting longer than
90 minutes consecutively for ≥ 3 days/week
• Eligible infants underwent a urine test to exclude urinary tract infection.
Exclusion criteria: infants with known organic disorders or positive to faecal blood test
Interventions Intervention 1 (20 infants): 1.2 mg/kg cimetropium bromide
Intervention 2 (20 infants): 2.0 mg/kg cimetropium bromide
Administration: Both drugs were administered 1 hour before bottle feeding. Treatment
lasted 2 weeks, with 3 visits during this period to evaluate general conditions, symptoms
and adverse effects. Parents could use pacifiers such as abdominal massage, clyster or a
trip in a car. No diet modifications were performed
Duration of study: 2 weeks
Outcomes During the visits, evaluation was based on the diary. The mother had to report the
following every day for 2 weeks: number of crying crises, duration of longest crisis,
weight changes and number of evacuations. Improvement in symptoms was classified by
the following scale: ’- 2’ the longest crisis increased by more than 60 minutes compared
with basal; ’- 1’ the longest crisis increased by 30 to 60 minutes compared with basal;
’0’ no improvement compared with basal; ’+ 1’ the shortest crying episode reduced by
30 to 60 minutes compared with basal; ’+ 2’ the shortest crying episode reduced by
more than 60 minutes compared with basal. Parental satisfaction was evaluated during
the second visit. Child temperament and treatment safety (heart frequency [heart rate],
body temperature, number of episodes of diarrhoea) were evaluated during treatment
Notes Country: Italy
Funding source: Study authors reported no information about funding.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement.
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
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Gomirato 1989 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: No information was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: No information was reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Four infants receiving the drug
at the higher dosage (2mg/kg) showed con-
stipation and stopped treatment before the
end of the study period, but study authors
did not explain how they considered these
infants in the analyses
Selective reporting (reporting bias) Unclear risk Comment:Outcomeswere not clearly pre-
specified in the Methods section
Other bias Unclear risk Comment: Information was insufficient to
permit a judgement of baseline balance be-
tween the 2 groups
Grunseit 1977
Methods Randomised, double-blind, cross-over trial
Participants Sample size: 25 infants. 3 dropouts
Setting: not reported
Sex: boys (41%)
Mean age: 5.4 (SD not reported) weeks at baseline; range 3 to 12 weeks at baseline
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: not reported
Feeding: not reported
Birth order: 16 first-born, 4 second-born, 2 fourth-born
Inclusion criteria: infants suffering from infant colic. Diagnostic criteria for inclusion
were postprandial attacks of screaming and crying that were unabated by maternal com-
forting, vomiting and sleep disturbance
Exclusion criteria:
• Babies who had received prior treatment with dicyclomine syrup
• Infants with congenital abnormalities or other co-existing disease
Interventions Intervention (22 infants): dicyclomine hydrochloride syrup, 5 mg per 5 mL
Control (22 infants): placebo; appeared identical to dicyclomine
Administration: Parents were instructed to give 5 mL of syrup to the baby 15 to 20
minutes before 4 feeds/d. Infants received treatment or placebo for 1 week
Duration of study: 2 weeks
Washout period: none
48Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Grunseit 1977 (Continued)
Outcomes Colic symptoms: postprandial crying, postprandial vomiting, sleep disturbance. If
symptoms were assessed as mild, they were rated ’1’, moderately severe ’2’ and severe ’3’.
If absent, ’0’. The mother was provided a diary card to record symptoms, time, severity
and medication used. At the end of 1 week, the baby was brought back to the physician
for assessment of each symptom and completion of the scoring form. After the second
week of therapy, the baby was brought back for final assessment
Notes Country: Australia
Funding source: Study authors did not specify whether they had received financial
support for the study. Drug and placebo were supplied by the company (Richardson-
Merrell)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement.
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: The mother was provided di-
cyclomine hydrochloride syrup or identical
appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: The mother was provided di-
cyclomine hydrochloride syrup or identical
appearing placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment:A total of 22 of 25 infants com-
pleted the study: 3 infants were excluded, 2
failed to return for the final visit (1 taking
dicyclomine and 1 taking placebo) and a
third infant was excluded because his con-
dition worsened during the placebo phase,
requiring hospitalisation
Selective reporting (reporting bias) Unclear risk Comment: Study outcomes were not
clearly prespecified.
Other bias High risk Comment: No washout period was ap-
plied.
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Hwang 1985
Methods Placebo-controlled, cross-over trial
Participants Sample size: 30 infants with colic. Dropouts/withdrawals not reported
Setting: not reported
Sex: not reported
Mean age: 4.5 (SD not reported) weeks; range not reported
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: 4.9 (SD 3.7) hours
Feeding: not reported
Birth order: not reported
Inclusion criteria:Crying was diagnosed as infantile colic if it lasted longer than 3 hours
a day and occurred more than 3 days a week
Exclusion criteria: not reported
Interventions Intervention (30 infants): dicyclomine hydrochloride, 5 mg 4 times/d
Control (30 infants): placebo; designed to have the same taste, smell, colour and texture
as the active solution
Administration: Infants were given placebo and dicyclomine, each for 1 week, with the
order counterbalanced
Duration of study: 2 weeks
Washout period: no information
Outcomes Crying time: mean daily hours of crying (based on crying diary completed by parents)
. Parents were interviewed before and after treatment to obtain background data and
to evaluate therapeutic efficacy. In addition, parents kept 24-hour records about their
infants’ crying, irritability and sleeping
The article also reported sleeping time, number of feeds and number of stools (before
and during treatment)
Notes Country: Sweden
Funding source: This study was supported by a grant from the First of May Flower
Annual Campaign for Children’s Health (Sweden)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Comment: It is not clearly reported whether treat-
ment order was assigned by randomisation
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was not de-
scribed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Placebowas designed to have the same
taste, smell, colour and texture as the active solu-
tion
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Hwang 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Placebowas designed to have the same
taste, smell, colour and texture as the active solu-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Information was insufficient to permit
a judgement.
Selective reporting (reporting bias) High risk Comment: Study outcomes were not clearly spec-
ified, and treatment results were not reported by
study period
Other bias Unclear risk Comment:No information about washout period
was reported.
Illingworth 1959
Methods Randomised, double-blind, cross-over trial
Participants Sample size: 20 infants, but 4 infants did not have the inert substance, and 1 did not
have the active drug
Setting: well-baby clinic at Jessop Hospital, Sheffield
Mean age: not reported (SD not reported); range not reported. Simply states that all
infants were younger than 8 weeks
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: not reported
Feeding: not reported
Birth order: not reported
Inclusion criteria:
• Condition for inclusion into the study was the mother’s statement that screaming
continued unabated when the baby was picked up.
• Diagnosis was based on rhythmical attacks of screaming in the evening.
Exclusion criteria: not specified
Interventions Intervention (20 infants): dicyclomine hydrochloride, half teaspoon (approximately 5
mg) before the 6 PM feed
Control (16 infants): placebo, half teaspoon (approximately 5 mg) before the 6 PM
feed
Administration: The doctor prescribed dicyclomine hydrochloride, and the pharma-
cist dispensed dicyclomine or inert substance by random sampling. After 1 week, the
medicine was prescribed again, and the pharmacist gave the opposite of what she had
given before. Only the pharmacist knew which material (drug or placebo) the child had
received
Duration of the study: 2 weeks
Washout period: no information
51Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Illingworth 1959 (Continued)
Outcomes The child was seen 1 week after the start of treatment, and the mother’s word about
colic was reported. Results were graded from ’- 3’ to ’+ 3’ as follows: ’+ 1’ child slightly
better, ’+ 2’ definitively better but still with some discomfort, ’+ 3’ infant with very great
improvement and free from symptoms, ’- 1’ infant slightly worse
Notes Country: England
Funding source: Study authors did not specify whether they had received financial
support for the study; drug and placebo were supplied by the company, Merrell National
(UK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment:No information about random
sequence generation was reported
Allocation concealment (selection bias) Low risk Comment: Pharmacist dispensed dicy-
clomine or an inert substance by random
sampling
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Parental blinding was per-
formed. Only the pharmacist knew which
material the child had received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Parental and paediatrician
blinding was performed.Only the pharma-
cist knew which material the child had re-
ceived
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Four infants did not have the
inherited substance, and 1 did not have the
active drug
Selective reporting (reporting bias) High risk Comment: Study authors did not report
the results of each study period by treat-
ment group (dicyclomine or placebo)
Other bias Unclear risk Comment:No information about washout
period was reported.
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Markestad 1997
Methods Randomised, double-blind, cross-over trial
Participants Sample size: 20 consecutive infants; 1 infant was excluded because of organic disease
Setting: recruited from public healthcare clinics
Sex: 13 boys, 6 girls
Mean age: 7.3 (SD 3.4) weeks; range not reported
Mean weight: 3502 (SD 570) grams
Mean duration of colic: 5.2 (SD 3.0) weeks
Mean crying: 5.7 (SD 2.6) hours
Feeding: breast fed (17 purely breast fed, 2 partially breast fed)
Birth order: not reported
Inclusion criteria:
• Colic was defined as crying for a minimum of 3 hours per day 3 days a week for
the past 3 weeks.
• Infants were between 3 weeks and 3 months old.
Exclusion criteria: not specified
Interventions Intervention (19 infants): sucrose, 12% solution in distilled water
Placebo (19 infants): distilled water
Administration:One bottle containing sucrose and 1 containing placebo were arranged
in numbered pairs. Parents received oral and written instructions to give 2 mL of the
distributed solution by syringe over 30 to 60 seconds, while holding the infant in their
arms, when the infant continued to cry after attempts of consoling by feeding, by chang-
ing the nappy or by carrying had failed. Repeat visits were scheduled 3 to 4 and 6 to 8
days after the first visit, and a telephone interview was conducted 3 to 4 days after the
last visit. On each visit, the bottle was returned, and the other of the pair was distributed
Duration of study: 8 days
Washout period: no information
Outcomes The infant was examined clinically at repeated visits, and on each contact (visit or
telephone contact), the parent described the effect of the last treatment on a 5-point
scale: ‘getting worse’ to ‘no improvement’, ‘some improvement’, ‘marked improvement’,
and ‘complete stop of crying after each dose’
Notes Country: Norway
Funding source: Study authors did not report whether the study had received support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Study authors did not describe
the randomisation method.
Quote: “each infant was randomised to a
number and which of the pair of bottles to
be tried first by two separate draws using
the sealed envelope technique”
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Markestad 1997 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: sealed envelope technique;
not reported whether the envelopes were
opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Sucrose as a 12% solution in
distilled water and placebo as distilled wa-
ter were prepared by a pharmacist, who
also arranged and kept the coding, and
distributed treatment in identical coloured
glass bottles
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Only the pharmacist knew
which material the child had received
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 19 infants completed the study
and were analysed.
Selective reporting (reporting bias) High risk Comment: Study authors did not report
results by study period.
Other bias Unclear risk Comment:No information about washout
period was reported.
Metcalf 1994
Methods Randomised, double-blind, cross-over trial
Participants Sample size: 92 infants enrolled; 9 infants excluded: 8 for failure to keep follow-up visits
and 1 for infection. Total of 83 infants were included in the analysis
Setting: 3 general paediatric practices in distinct geographic regions
Sex: boys (49.4%)
Mean age: not reported (SD not reported); range 2 to 8 weeks
Mean weight: not reported
Mean duration of colic: not reported; 24% had severe colic at baseline
Mean crying: not reported
Feeding: breast fed (26.5%)
Birth order: not reported
Inclusion criteria:
• Infants with crying sufficient to meet Wessel’s criteria
• Aged 2 to 8 weeks, appropriate gestational age
• Weight gain ≥ 5 ounces per week
• Normal history and physical exam
Exclusion criteria:
• Infants with congenital or acquired abnormalities that might predispose them to
irritability
• Infants with prior or currently diagnosed illness or a history of treatment for
hyperbilirubinaemia
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Metcalf 1994 (Continued)
Interventions Intervention (83 infants): simethicone; 0.3 cc of simethicone solution before each meal
Control (83 infants): placebo
Administration: Trial consisted of 2 study periods, each of approximately 1 week (mini-
mum 3 days; maximum 10 days). Infants first received simethicone or placebo according
to a schedule determined by random number tables, followed by the alternate substance
for the second study period. Carers were given a bottle of coded medication and were
instructed to give 0.3 mL with each feeding
Duration of study: 2 weeks
Washout period: 1 day
Outcomes Treatment efficacy was measured by interviews, 3- to 4-hour behavioural observations
and 24-hour records inwhich parents described infants’ crying, fussing, eating and stools.
Parents were asked to record in the daily diary each administration of medication and to
provide written comments on events deemed noteworthy, including any modifications
in dietary habits or feeding schedule. At the end of each day, parents were to rate their
child’s colic compared with when they had first sought treatment for the infant. They
used a 5-point scale to identify the child’s symptoms as follows: ’+ 2’, definitely better or
symptom-free; ’+ 1’, possibly better; ’0’, the same; ’- 1’, possibly worse; ’- 2’, definitely
worse. After the first study period, carers returned the diary and any unused medication
to the physician’s office, or they gave these items to a nurse study co-ordinator during a
home visit. Responders to simethicone or to placebo were infants judged by the carer to
have had a positive response (+ 1, + 2) only to simethicone or only to placebo
Notes Country: United States
Funding source: This study was supported by a grant from Smart Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Infants first received either sime-
thicone or placebo, based on a schedule de-
termined by random number tables, fol-
lowed by the alternate substance for the sec-
ond study period”
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Caregivers were given a bottle of
coded medication”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Caregivers were given a bottle of
coded medication”.
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Metcalf 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Information was insufficient to
permit a judgment; researchers reported
only withdrawals - 8 infants were excluded
for failure to keep follow-up visits, and 1
child developed upper air respiratory infec-
tion and was excluded
Selective reporting (reporting bias) High risk Comment: Study authors did not report
results by study period.
Other bias Low risk Comment:One-daywashoutwas planned.
Montaseri 2013
Methods Randomised, double-blind, multi-centre, placebo-controlled trial
Participants Sample size: 60 infants. 17% of infants were withdrawn from the study for non-atten-
dance at clinic or an incomplete booklet
Setting: 6 clinics affiliated with Shiraz University of Medical Sciences
Sex: boys (50%)
Mean age: not reported (SD not reported); range 1 to 4 months. The largest age group
consisted of 2-month-old infants in both treatment and control groups
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: not reported
Feeding: not reported
Birth order: first born (intervention 50%, control 58%)
Inclusion criteria: infants with colic pain (selected and examined by a physician)
Exclusion criteria: infants with other problems/disorders
Interventions Intervention (26 infants): Fumaria extract 2.5 cc was prescribed to be taken 3 times a
day for a week
Control (24 infants): placebo
Mothers were required to refrain from using any other type of medicine or treatment
during this period. Fumaria extract and placebo were prepared and encoded according
to the table of random numbers. These codes were kept secret until data collection by a
pharmacist was complete, and they were revealed after analysis was performed and labels
on reports were prepared
Administration: 2.5 cc of Fumaria extract was prescribed to be taken by infants 3 times
a day for a week
Duration of study: 1 week
Outcomes Treatment efficacy was measured by mothers via a booklet diary. Parents were asked to
come to the clinic after the treatment period to hand in the booklet and, at the same time,
evaluate colic pain in their infant. Information recorded by mothers included frequency
and length of crying and frequency of waking up owing to colic pain per day
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Montaseri 2013 (Continued)
Notes Country: Iran
Funding source: This study was supported by the Vice Chancellor of Shiraz University
of Medical Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Fumaria extract and placebo
were prepared and encoded according to
the table of random numbers. After written
informed consent was obtained from the
mothers of the infants, control and treat-
ment groups were established on the basis
of labels
Allocation concealment (selection bias) Low risk Comment: Fumaria extract and placebo
were prepared and encoded according to
the table of random numbers. These codes
were kept secret until data collection by a
pharmacist was complete, and theywere re-
vealed after analysis was performed and la-
bels on reports were prepared. After written
informed consent was obtained from the
mothers of the infants, control and treat-
ment groups were established on the basis
of these labels
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Information was insufficient to
permit a judgement.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Information was insufficient to
permit a judgement.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment:17%of infantswerewithdrawn
from the study for non-attendance at clinic
or an incomplete booklet. The number of
infants randomised to each group was not
reported, nor was the number of dropouts
in each group
Selective reporting (reporting bias) Low risk Comment: Study authors reported results
for outcomes declared in the Methods sec-
tion
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Montaseri 2013 (Continued)
Other bias Low risk Comment: At baseline, no significant dif-
ferences in demographic characteristics and
colic criteria were evident between the 2
groups
Savino 2002
Methods Randomised, double-blind, placebo-controlled trial
Participants Sample size: 97 infants with colic. Of these 97 infants, 11 (5 from the treatment group
and 6 from the control group) dropped out; 7 did not come to the second visit, 2 were
excluded because of fever and 2 were excluded because of gastroenteritis
Setting: Children’s Hospital Regina Margherita
Sex: not reported
Mean age: not reported (SD not reported); range 15 to 60 days
Mean weight: not reported
Mean duration of colic: not reported
Mean crying: cimetropium bromide 17.3 (SD 12.6) minutes; placebo 47.5 (SD 28.5)
minutes
Feeding: exclusively breast fed
Birth order: not reported
Inclusion criteria:
• Healthy infants with regular growth
• 15 to 60 days old
• Diagnosis of infantile colic based on Wessel criteria
Exclusion criteria: not reported
Interventions Intervention (43 infants): cimetropium bromide 3 drops/kg (1.2 mg/kg)
Control (43 infants): placebo; solution with the same colour, smell, taste and package
but with no pharmacological properties
Administration: Treatment should be administered at the onset of each crisis, defined
as inconsolable full-force crying with typical characteristics of infantile colic (legs flexed
over the abdomen, fists closed, meteorism) and no response to common consolation
procedures, such as pacifier use, rocking or dull continuous background noise
Duration of study: not reported
Outcomes Therapy was considered efficacious if crying ended within 15 minutes of administration
of the compounds. Responders were children who stopped crying within this time. Par-
ents received a structured diary in which they recorded daily (1) time crying began, time
medication was given and time crying ended; and (2) side effects observed (meteorism,
vomiting, sleepiness, restlessness, inappetence, cutaneous reactions, constipation, diar-
rhoea, respiratory distress or apnoea)
Notes Country: Italy
Funding source: This study was not supported; the drug and placebo were provided by
Pharma S.P. A., Carugate (Milan)
Risk of bias
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Savino 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Sequentially to recruitment each
infant was assigned randomly to one of the
two groups”. Insufficient information was
reported
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Placebowas a solution with the
same colour, smell, taste and package but
with no pharmacological properties
Quote: “Neither doctors nor parents knew
which infants received treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither doctors nor parents knew
which infants received treatment”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 11 infants (5 from the treat-
ment group and 6 from the control group)
dropped out. 7 did not come to the second
visit, 2 were excluded because of fever and
2 were excluded because of gastroenteritis.
Reasons for missing data could be related
to treatment, but study authors did not re-
port reasons for missing data by arm
Selective reporting (reporting bias) Low risk Comment: Study authors reported results
for all outcomes declared in the Methods
section
Other bias Low risk Comment: Before the study began, the av-
erage number of crises each day and average
crying durationwere similar in both groups
Savino 2005
Methods Randomised, double-blind, placebo-controlled trial
Participants Sample size: 93 colicky infants. Of these 93 infants, 5 (2 from the treatment group
and 3 from the control group) dropped out: 2 did not come to the second visit, 3 were
excluded because of fever. Nobody withdrew because of problems related to the trial;
therefore, the study population may be considered homogeneous
Setting: recruited from patients seen at the Department of Pediatrics of the Regina
Margherita Children’s Hospital, University of Turin
Sex: boys (46.6%)
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Savino 2005 (Continued)
Mean age: herbal agents 4.2 (SD 1.4) months, placebo 4.4 (SD 1.6) months; range not
reported
Mean weight: herbal agents 3420 (SD 390) grams, placebo 3510 (SD 330) grams
Mean duration of colic: not reported (SD not reported)
Mean crying: herbal agents 201.2 (SD 18.3) minutes, placebo 198.7 (SD 16.9) minutes
Feeding: not specified
Birth order: not specified
Inclusion criteria:
• Breast fed healthy infants with regular growth
• 21 to 60 days old
• Born at term (gestational age: 38 to 42 weeks)
• Birth weight between 2500 and 4000 grams
• No clinical evidence of gastroenterological disease
• Apgar score > 7 at 5 minutes after birth
Exclusion criteria: infants receiving any medication that could affect abdominal symp-
toms, such as antibiotic and probiotic drugs
Interventions Intervention 1 (41 infants): phytotherapeutic agent (extracts of Matricaria recutita,
Foeniculum vulgare andMelissa officinalis). Each dose of herbal agent consisted of 1 bottle
with tank cap containing Foeniculum vulgare Miller Var. Dulce (164.29 mg), Matricaria
recutita L. (177.69 mg),Melissa officinalis L. (96.89 mg), vitamin B1 (0.85 mg), calcium
pantothenate (3.24 mg), vitamin B6 (1.20 mg), maltodextrin (dose not specified) and
Syloid 244 FP (dose not specified) (ColiMil, Milte-Milan, Italy). At the administered
dosage, the herbal agent provides Matricaria recutita L. 71.10 mg/kg/d, Foeniculum
vulgare Miller Var. Dulce 65.71 mg/kg/d and Melissa officinalis L. 38.75 mg/kg/d.
Control (47 infants): placebo. Placebo looking like the phytotherapeutic agent with
regard to colour, smell, taste and package, but containing only vitamins. Each dose
of placebo consisted of 1 identical bottle with tank cap containing water obtained by
inverted osmosis, fructose, pineapple flavour, citric acid and sorbate potassium.
Administration: Both herbal agent and placebo were administered twice a day at 5 PM
and 8 PM, some minutes before feeding, at a dosage of 2 mL/kg/d. Infants had to take
treatment consecutively for 7 days
Duration of study: 21 days
Outcomes Parents wrote a daily structured diary, recording (1) the start of crying time - when the
medication was administered, (2) the end of crying time and (3) any side effects they
observed for the 7 days of therapy and until day 21 from enrolment (vomiting, sleepiness,
restlessness, inappetence, cutaneous reactions, constipation, diarrhoea). Before starting
treatment, parents were invited to record data concerning daily crying time for 3 days
(day − 2; day − 1; day 0). At days 1 and 7, infants were seen in the department, and
parents gave the diary to researchers. At day 21 after baseline, mothers were asked to
complete a questionnaire about crying time during the observation period. To ensure
that all parents noted crying time in a uniform way, and to ensure that infants were given
medication correctly, 1 researcher was always available by phone to help parents. Therapy
was considered efficacious if crying time was reduced by ≥ 50% per day; responders
were infants who showed such a reduction in crying time
Notes Country: Italy
Funding source: Study authors did not report whether the study received any support
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Savino 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement.
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Placebo looked like the phy-
totherapeutic agent with regard to colour,
smell, taste and package
Quote: “Neither doctors nor parents knew
whether the infants received treatment or
not”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither doctors nor parents knew
whether the infants received treatment or
not”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 5 infants (2 from the treat-
ment group and 3 from the placebo group)
dropped out - 2 did not come to the second
visit, and 3 were excluded because of fever,
but nobody withdrew because of problems
related to the trial
Selective reporting (reporting bias) Low risk Comment: Study authors reported results
for all outcomes declared in the Methods
section
Other bias Low risk Comment: No significant differences be-
tween groups at baseline were reported
Sethi 1988
Methods Double-blind, randomised, placebo-controlled, cross-over trial
Participants Sample size: 26 children; no dropouts/withdrawals
Setting: not reported
Sex: boys (40%)
Mean age: not reported (SD not reported); range 1 week to 3 months
Mean weight (SD): not reported
Meanduration of colic:not reported (SDnot reported); states simply that no differences
in frequency of symptoms at the beginning of treatment were noted between groups
Mean crying: not reported
Feeding: not reported
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Sethi 1988 (Continued)
Birth order: not reported
Inclusion criteria: infants with diagnosis of colic
Exclusion criteria: not specified
Interventions Intervention (n = 26): simethicone; 25 participants received 1 dropper load of medica-
tion (20 mg) and 11 received 2 droppers (dose not reported) before evening feeds, since
symptoms were nocturnal
Control (n = 26): placebo
Administration: Therapy was administered as a suspension containing 40 mg/mL sime-
thicone and as a matching placebo suspension. Parents were issued a coded trial medi-
cation, and after 1 week, the trial medication was returned; parents then were issued the
alternative trial medication for the coming week
Duration of study: 2 weeks
Washout period: none
Outcomes Parents were asked to record (1) daily frequency of crying and (2) amplitude for crying
attacks, using a 4-point rating scale. Parents were also asked to record (3) the number,
nature and consistency of infant stools and (4) any perceived adverse effects
Notes Country: England
Funding source: Study authors did not report whether the study received support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement.
Allocation concealment (selection bias) Unclear risk Comment: Method of concealment was
not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Parents were issued with a coded
trial medication”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Parents were issued with a coded
trial medication”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All infants completed the
study.
Selective reporting (reporting bias) High risk Comment: Study authors did not clearly
report results for all outcomes and did not
report results of each treatment by study
period
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Sethi 1988 (Continued)
Other bias High risk Comment: No washout period was
planned.
Weissbluth 1984
Methods Randomised, double-blind, placebo-controlled trial
Participants Sample size: 48 infants; 6 families did not complete the treatment period (1 dicyclomine
hydrochloride, 5 placebo)
Setting: Infants received general paediatric care from a physician on staff at Children’s
Memorial Hospital
Sex: boys (58%)
Mean age: 4 (SD not reported) months; range not reported
Mean weight: 4.4 (SD not reported) kilograms
Mean duration of colic: 5 weeks
Mean crying: not reported
Feeding: not reported
Birth order: 50% first born
Inclusion criteria: infants with colic defined as unexplained irritability, agitation, fussi-
ness, crying lasting > 3 hours per day and occurring more than 3 days/week for longer
than 3 weeks (Wessel definition)
Exclusion criteria: not specified
Interventions Intervention (24 infants): dicyclomine hydrochloride
Control (24 infants): placebo
Administration: Researchers dispensed 180 mL (6 oz) of cherry syrup (placebo) or
dicyclomine hydrochloride in identical appearing bottles
Each family received a syringe-type measuring device to administer the study colic
medicine. Dosage instructions were derived from a pilot study and were based on min-
imising apparent dose-related adverse effects observed during the study. Medicine was
given for a minimum of 14 days and was started at the lowest dose listed, given once in
the morning, once at noon and once in the evening. Investigators reported no baseline
differences between treatment groups. 42 of the 48 eligible infants received the medica-
tion for 14 days or longer
Duration of study: 14 days
Outcomes The family received a 14-day diary in which to record daily hours of colic, numbers of
night awakenings and side effects. The definition of drug treatment outcome was based
on analysis of the second week of study treatment. The categorical definition of colic
was the same as for the first eligibility criterion of the study. Thus, infants with spells of
unexplained crying for less than 3 hours/d (based on information reported in the diary)
or longer than 3 hours/d on fewer than 3 days/week were considered to not have colic
Notes Country: USA
Funding source: Study authors did not report whether the study received any support
Risk of bias
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Weissbluth 1984 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Information was insufficient to
permit a judgement.
Allocation concealment (selection bias) Low risk Comment: Pharmacists at Children’s
Memorial Hospital randomly assigned the
group allocation as each eligible infant
was enrolled in the study. During the en-
tire study, the code-determining group was
known only to the pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Placebo or dicyclomine was
dispensed in identical appearing bottles la-
belled only “Colic study medicine”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Placebo or dicyclomine was
dispensed in identical appearing bottles la-
belled only “Colic study medicine”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 6 families did not complete
the 14-day treatment period because they
noted “no improvement” and were consid-
ered as treatment failures before group al-
location was known
Selective reporting (reporting bias) Low risk Comment: Study authors reported results
for all outcomes declared in the Methods
section
Other bias Low risk Comment: No group differences were
noted between infants given drug or
placebo in terms of any baseline character-
istic
Weizman 1993
Methods Randomised, double-blind, placebo-controlled trial
Participants Sample size: 72 infants (36 herbal tea, 36 placebo) were enrolled in the study. 4 infants
were excluded during the study: 3 for acute illness (2 from tea arm, 1 from placebo arm)
, and 1 because of poor parental compliance. 68 were included in the analysis
Setting: primary community-based paediatric clinics in the Beer-Sheva area, in Israel
Sex: boys (38% of 68)
Mean age: herbal tea 21.1 (SD 9.3) days, placebo 24.6 (SD 7.6) days; range not reported
Mean weight: herbal tea 3116 (SD 1060) grams, placebo 3201 (SD 1088) grams
Mean duration of colic: not reported
Mean crying: not reported
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Weizman 1993 (Continued)
Feeding: breast fed (herbal tea 72%, placebo 67%)
Birth order: first child (herbal tea 59%, placebo 66%)
Inclusion criteria: infants with colic according to Wessel definition
Exclusion criteria:
• Prematurity
• Weight gain < 150 mg/week
• Acute or chronic illness and drug therapy
Interventions Intervention (33 infants): herbal tea preparation (Calma Baby Bonomelli) containing
fennel, chamomile, vervain, licorice, balm mint
Control (35 infants): placebo. The placebo preparation consisted of an instant powder
of glucose and natural flowers only, with no herbs. The smell and taste of the placebo
and the tea were similar
Administration: Tea was offered to infants with every episode of colic, up to 150 mL/
dose, but no more than 3 times a day. Tea powder was dissolved in water according to
the manufacturer’s instructions. Treatment was administered for 1 week. No significant
differences were noted between 2 treatment arms
Outcomes Evaluation of the 2 groups was based on the following 3 measures:
• Number of night awakenings requiring parental response
• Elimination of colic based on the same definition adopted as inclusion criteria
(crying < 3 hours/d or > 3 hours/d but for < 3 days/week)
• Colic improvement (5-point score based on parental judgement: ’- 1’ worsening;
’0’ no change; ’+ 1’ mild improvement; ’+ 2’ moderate improvement; ’+ 3’ significant
improvement)
Families received a diary in which to record total daily hours of colic, numbers of night
awakenings, a 5-grade improvement score and adverse effects. Parental diaries covered 7
days with no therapy and 7 days with treatment
Notes Country: Israel
Funding source: This study was supported by Materna Laboratories, Maabarot, Israel
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “infants were randomly assigned to
receive either tea or placebo”
Comment: Information was insufficient.
Allocation concealment (selection bias) Low risk Comment: During the entire study, the
code determining group allocation was
known only to the pharmacists
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The smell and taste of the placebo
and the tea were similar; both were packed
in identical appearing cans; the code of
group allocation was known only by the
pharmacist”
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Weizman 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The code was known only by the
pharmacist”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 4 infants were excluded dur-
ing the study: 3 (2 tea and 1 placebo) be-
cause of acute illness, and 1 (tea) because
of poor parental compliance. Study authors
excluded these infants from the analyses be-
cause of exclusion criteria
Selective reporting (reporting bias) Low risk Comment: Study authors reported study
results for all outcomes.
Other bias Low risk Comment: Analysis of infant characteris-
tics (gender, age, feedingmethod) and colic
severity after 7 days of no-treatment re-
vealed no significant differences between
the 2 groups
CHC: child health centre.
SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barr 1999 Case-control study (not an experimental study)
Becker 1988 Not a comparative study. A control arm was not planned; all participants were assigned to simethicone treatment
Benjamins 2013 Cross-sectional study (not an experimental study)
Koonce 2011 Commentary on a clinical study (not an experimental study)
NCT00655083 Not a comparative study (phase I study)
NCT01532518 Not eligible participants (infants with feeding intolerance)
NCT02708238 Not an eligible comparison. This study compared Matricaria chamomilla L., Melissa officinalis L. and tyndallised
L. Acidophilus (H122) and L reuteri DSM 17938 (108 CFU) with simethicone.
Oggero 1994 Not an eligible comparison. This study compared dicyclomine with dietary modifications
66Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Savino 2007 Not an eligible comparison. This study compared simethicone with Lactobacillus.
Characteristics of ongoing studies [ordered by study ID]
NCT01258153
Trial name or title Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic (no-cry)
ClinicalTrials.gov identifier: NCT01258153
Double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral
administration of nepadutant in infant colic
Methods Study type: intervention
Study design: randomised, double-blind
Participants Inclusion criteria:
• Healthy infants with diagnosis of infant colic according to the following, modified Wessel criterion:
“paroxysms of irritability, fussing or crying that start and stop without obvious cause for > 3 hours/day, > 3
days/week for one week”
• Age > 4 weeks and < 20 weeks
• Infants breast fed, mixed fed or formula fed with a stable dietary regimen
• Normal growth
• History of no adequate response to conventional treatment alternatives, which makes infants in need
of medical treatment
• Willingness to refrain from use of antimuscarinic drugs, simethicone, dimethicone or antacids during
the study period
Exclusion criteria:
• Clinical evidence of allergies or other diseases that may cause crying and/or fussiness or may interfere
with absorption or clearance of the drug
• Suspect of gastroesophageal reflux disease (GERD)
• Suspect of cow’s milk allergy
Interventions Number of arms: 3
• Nepadutant low dose
• Nepadutant high dose
• Placebo
Administration: oral; once daily for 7 days
Outcomes Primary outcome measure:
• Absolute change in mean daily crying and fussing time for 3 consecutive days while on treatment vs
baseline [time frame: 1 week] [designated as safety issue: no]
Secondary outcome measures:
• Percentage of ’responder’ babies at end of treatment period [time frame: 1 week ] [designated as safety
issue: no]
• Absolute change in overall parental judgement after first dose of treatment, at the end of treatment and
after treatment discontinuation vs baseline [time frame: 10 days] [designated as safety issue: no]
• Safety and tolerability assessed in terms of frequency and severity of adverse events (AEs) as well as
frequency of clinically significant changes in physical examination findings and lab test results [time frame:
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NCT01258153 (Continued)
up to 4 weeks] [designated as safety issue: yes]
Starting date November 2010
Contact information Study chair: Sybille Koletzko, Dr. v. Haunersches Kinderspital Ludwig Maximilians University D-80337
München, Germany
Notes This phase IIa study is designed as a multi-centre, multi-national, randomised, double-blind, placebo-con-
trolled study in 3 parallel groups, with the aim to evaluate the efficacy and safety of nepadutant given at 2
oral doses once daily for 7 days vs placebo in the treatment of infantile colic
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D A T A A N D A N A L Y S E S
Comparison 1. Simethicone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Responders 2 220 Risk Ratio (IV, Random, 95% CI) 0.95 [0.73, 1.23]
Comparison 2. Herbal agents versus placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 3 279 Mean Difference (IV, Random, 95% CI) 1.33 [0.71, 1.96]
2 Sensitivity: reduction in crying
duration
2 209 Mean Difference (IV, Random, 95% CI) 1.09 [0.11, 2.08]
3 Responders 3 277 Risk Ratio (IV, Random, 95% CI) 2.05 [1.56, 2.70]
Comparison 3. Sugar versus no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 4. Dicyclomine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Responders 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 5. Cimetropium bromide versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Responders 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 Reduction in frequency of crying
episodes
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 6. Cimetropium bromide 1.2 mg/kg versus cimetropium bromide 2.0 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in frequency of crying
episodes
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 7. Simethicone versus herbal agents (Mentha piperita)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Responders 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Reduction in frequency of crying
episodes
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 8. Sugar versus herbal agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in crying duration 1 Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Simethicone versus placebo, Outcome 1 Reduction in crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 1 Simethicone versus placebo
Outcome: 1 Reduction in crying duration
Study or subgroup Simethicone Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Danielsson 1985 (1) 27 4.24 (2.18) 27 4.37 (2.55) -0.13 [ -1.40, 1.14 ]
-4 -2 0 2 4
Favours simethicone Favours placebo
(1) Final values
Analysis 1.2. Comparison 1 Simethicone versus placebo, Outcome 2 Responders.
Review: Pain-relieving agents for infantile colic
Comparison: 1 Simethicone versus placebo
Outcome: 2 Responders
Study or subgroup Simethicone Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Danielsson 1985 19/27 17/27 38.8 % 1.12 [ 0.77, 1.63 ]
Metcalf 1994 41/83 48/83 61.2 % 0.85 [ 0.64, 1.14 ]
Total (95% CI) 110 110 100.0 % 0.95 [ 0.73, 1.23 ]
Total events: 60 (Simethicone), 65 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours placebo Favours simethicone
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Analysis 2.1. Comparison 2 Herbal agents versus placebo or no intervention, Outcome 1 Reduction in
crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 2 Herbal agents versus placebo or no intervention
Outcome: 1 Reduction in crying duration
Study or subgroup Herbal agent Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alexandrovich 2003 62 0.67 (1.16) 59 0.09 (0.03) 32.7 % 0.58 [ 0.29, 0.87 ]
Arikan 2008 35 1.91 (0.91) 35 0.09 (0.21) 32.4 % 1.82 [ 1.51, 2.13 ]
Savino 2005 41 2.07 (0.25) 47 0.48 (0.11) 34.9 % 1.59 [ 1.51, 1.67 ]
Total (95% CI) 138 141 100.0 % 1.33 [ 0.71, 1.96 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 46.95, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 4.18 (P = 0.000029)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours herbal agent
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Analysis 2.2. Comparison 2 Herbal agents versus placebo or no intervention, Outcome 2 Sensitivity:
reduction in crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 2 Herbal agents versus placebo or no intervention
Outcome: 2 Sensitivity: reduction in crying duration
Study or subgroup Herbal agent Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alexandrovich 2003 62 0.67 (1.16) 59 0.09 (0.03) 49.0 % 0.58 [ 0.29, 0.87 ]
Savino 2005 41 2.07 (0.25) 47 0.48 (0.11) 51.0 % 1.59 [ 1.51, 1.67 ]
Total (95% CI) 103 106 100.0 % 1.09 [ 0.11, 2.08 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 43.41, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours herbal agent
Analysis 2.3. Comparison 2 Herbal agents versus placebo or no intervention, Outcome 3 Responders.
Review: Pain-relieving agents for infantile colic
Comparison: 2 Herbal agents versus placebo or no intervention
Outcome: 3 Responders
Study or subgroup Herbal agent Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Savino 2005 35/41 23/47 55.6 % 1.74 [ 1.27, 2.40 ]
Weizman 1993 19/33 9/35 17.2 % 2.24 [ 1.19, 4.22 ]
Alexandrovich 2003 40/62 14/59 27.1 % 2.72 [ 1.66, 4.45 ]
Total (95% CI) 136 141 100.0 % 2.05 [ 1.56, 2.70 ]
Total events: 94 (Herbal agent), 46 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.31, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 5.14 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours herbal agent
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Analysis 3.1. Comparison 3 Sugar versus no intervention, Outcome 1 Reduction in crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 3 Sugar versus no intervention
Outcome: 1 Reduction in crying duration
Study or subgroup Sugar Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arikan 2008 35 1.81 (1.001) 35 0.09 (0.212) 1.72 [ 1.38, 2.06 ]
-2 -1 0 1 2
Favours placebo Favours sugar
Analysis 4.1. Comparison 4 Dicyclomine versus placebo, Outcome 1 Responders.
Review: Pain-relieving agents for infantile colic
Comparison: 4 Dicyclomine versus placebo
Outcome: 1 Responders
Study or subgroup Dicyclomine Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Weissbluth 1984 15/24 6/24 2.50 [ 1.17, 5.34 ]
0.05 0.2 1 5 20
Favours placebo Favours dicyclomine
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Analysis 5.1. Comparison 5 Cimetropium bromide versus placebo, Outcome 1 Reduction in crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 5 Cimetropium bromide versus placebo
Outcome: 1 Reduction in crying duration
Study or subgroup Cimetropium Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Savino 2002 43 17.3 (12.6) 43 47.5 (28.5) -30.20 [ -39.51, -20.89 ]
-50 -25 0 25 50
Favours cimetropium Favours placebo
Analysis 5.2. Comparison 5 Cimetropium bromide versus placebo, Outcome 2 Responders.
Review: Pain-relieving agents for infantile colic
Comparison: 5 Cimetropium bromide versus placebo
Outcome: 2 Responders
Study or subgroup Cimetropium Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Savino 2002 32/43 14/43 2.29 [ 1.44, 3.64 ]
0.05 0.2 1 5 20
Favours placebo Favours cimetropium
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Analysis 5.3. Comparison 5 Cimetropium bromide versus placebo, Outcome 3 Reduction in frequency of
crying episodes.
Review: Pain-relieving agents for infantile colic
Comparison: 5 Cimetropium bromide versus placebo
Outcome: 3 Reduction in frequency of crying episodes
Study or subgroup Cimetropium Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Savino 2002 43 2.9 (2.7) 43 3.3 (2.5) -0.40 [ -1.50, 0.70 ]
-2 -1 0 1 2
Favours cimetropium Favours placebo
Analysis 6.1. Comparison 6 Cimetropium bromide 1.2 mg/kg versus cimetropium bromide 2.0 mg/kg,
Outcome 1 Reduction in frequency of crying episodes.
Review: Pain-relieving agents for infantile colic
Comparison: 6 Cimetropium bromide 1.2 mg/kg versus cimetropium bromide 2.0 mg/kg
Outcome: 1 Reduction in frequency of crying episodes
Study or subgroup
Cimetropium
1.2 mg/Kg
Cimetropium
2 mg/Kg
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gomirato 1989 20 0.1 (0.1) 20 0.6 (0.4) -0.50 [ -0.68, -0.32 ]
-1 -0.5 0 0.5 1
Favours cimetropium 1.2 Favours cimetropium 2.0
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Analysis 7.1. Comparison 7 Simethicone versus herbal agents (Mentha piperita), Outcome 1 Reduction in
crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 7 Simethicone versus herbal agents (Mentha piperita)
Outcome: 1 Reduction in crying duration
Study or subgroup Simethicone Menthae piperita
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alves 2012 30 0.27 (0.17) 30 0.28 (0.23) -0.01 [ -0.11, 0.09 ]
-2 -1 0 1 2
Favoursmenthae piperita Favours simethicone
Analysis 7.2. Comparison 7 Simethicone versus herbal agents (Mentha piperita), Outcome 2 Responders.
Review: Pain-relieving agents for infantile colic
Comparison: 7 Simethicone versus herbal agents (Mentha piperita)
Outcome: 2 Responders
Study or subgroup Simethicone Menthae piperita Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alves 2012 13/30 12/30 1.08 [ 0.59, 1.97 ]
0.05 0.2 1 5 20
Favours simethicone Favours menthae piperita
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Analysis 7.3. Comparison 7 Simethicone versus herbal agents (Mentha piperita), Outcome 3 Reduction in
frequency of crying episodes.
Review: Pain-relieving agents for infantile colic
Comparison: 7 Simethicone versus herbal agents (Mentha piperita)
Outcome: 3 Reduction in frequency of crying episodes
Study or subgroup Simethicone Menthae piperita
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alves 2012 30 1.5 (0.6) 30 1.7 (0.5) -0.20 [ -0.48, 0.08 ]
-2 -1 0 1 2
Favours menthae piperita Favours simethicone
Analysis 8.1. Comparison 8 Sugar versus herbal agents, Outcome 1 Reduction in crying duration.
Review: Pain-relieving agents for infantile colic
Comparison: 8 Sugar versus herbal agents
Outcome: 1 Reduction in crying duration
Study or subgroup Sugar Herbal agents
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arikan 2008 35 1.81 (1.001) 35 1.91 (0.91) -0.10 [ -0.55, 0.35 ]
-2 -1 0 1 2
Favours herbal agents Favours sugar
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A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study N°infants
enrolled
N° infants
analysed
Mean age
(SD) in
weeks at
study en-
try
Male (%) Interven-
tion/
control
Loss
to follow-
up (%)
(interven-
tion/
control)
Study
treat-
ment du-
ration (in
days)
Study de-
sign
Outcomes
Akçam
2006
30 25 9.1 (5.9) 40 Glu-
cose (30%)
/placebo
16.7 4 Ran-
domised,
cross-over
Respon-
ders
Adverse ef-
fects
Alexan-
drovich
2003
125 121 4.3 (1.1) 45.5 Fen-
nel seed oil
emulsion/
placebo
4.6/1.7 7 Ran-
domised,
parallel-
arm
Respon-
ders (as re-
lief of colic
symp-
toms)
Cumula-
tive crying
time
(hours/
week)
Number of
doses/d
Consumed
mL/d
Adverse ef-
fects
Alves 2012 30 30 4.7 (1.6) 45.5 Sime-
thicone/
herbal
agents
(Mentha
piperita)
0 7 Ran-
domised,
cross-over
Respon-
ders (as im-
provement
in symp-
toms)
Frequency
of colic
episodes
(daily)
Daily colic
duration
(minutes)
Duration
of colic
Adverse ef-
fects
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Table 1. Summary of study characteristics (Continued)
Arikan
2008
175 105* 8.24 (2.
88)
55.5 Herbal tea
or sucrose/
no
treatment
0 7 Ran-
domised,
parallel-
arm
Crying
time
(hours/d)
Blomquist
1983
18 18 Range 2 to
14
44.4 Dicy-
clomine
plus sugar/
placebo
0 7 Ran-
domised,
cross-over
Respon-
ders (as im-
provement
in colic
severity)
Frequency
of crying
episodes
Danielsson
1985
27 27 4.8 (range
2 to 8)
44.4 Sime-
thicone/
placebo
0 7 Quasi-ran-
domised,
cross-over
Respon-
ders
Crying
time
(hours/d)
Time
sleeping
(hours/d)
Number of
feedings
Number of
stools
Gomirato
1989
40 40 4.4 40
Cimetropium
bromide
(1.2 mg/
kg)/
cimetropium
bromide
(2.0 mg/
kg)
0 14 Ran-
domised,
parallel-
arm
Respon-
ders (as im-
provement
in symp-
toms)
Number of
crying
episodes/d
Duration
of longest
episodes
(minutes)
Adverse ef-
fects
Grunseit
1977
25 22 5.4 (range
3 to 12)
40.9 Dicy-
clomine/
placebo
12.0 7 Ran-
domised,
cross-over
Score of
symptoms
(as contin-
uous mea-
sure)
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Table 1. Summary of study characteristics (Continued)
Hwang
1985
30 30 4 to 5 Not
reported
Dicy-
clomine/
placebo
0 7 Quasi-ran-
domised,
cross-over
Respon-
ders (as im-
provement
in symp-
toms)
Crying
time
(hours/d)
Sleeping
time
(hours/d)
Adverse ef-
fects
Illing-
worth
1959
16 16 < 8 Not
reported
Dicy-
clomine/
placebo
0 7 Ran-
domised,
cross-over
Score of
symptoms
Respon-
ders (as im-
provement
in symp-
toms)
Markestad
1997
19 19 7.3 (3.4) 68.4 Sucrose
(12%)/
placebo
0 8 to 12 Ran-
domised,
cross-over
Respon-
ders (as im-
provement
in symp-
toms)
Parental
satisfac-
tion
Metcalf
1994
83 83 Not
reported
49.4 Sime-
thicone/
placebo
0 7 (3 to 10) Ran-
domised,
cross-over
Respon-
ders (as im-
provement
in symp-
toms)
Montaseri
2013
60 50 8 (4 to 16) 50 Fumaria
extract/
placebo
17.0 7 Quasi-ran-
domised
Fre-
quency of
crying at-
tack
Crying du-
ration
Fre-
quency of
waking up
(all as cate-
gorical
variables)
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Table 1. Summary of study characteristics (Continued)
Savino
2002
97 86 Range 2 to
8
Not
reported Cimetropium
bromide/
placebo
9.8/13.0 3 Ran-
domised,
parallel-
arm
Respon-
ders
Adverse ef-
fects
Savino
2005
93 88 4.3 (1.5) 46.6 Herbal tea/
placebo
4.7/6.0 7 Ran-
domised,
parallel-
arm
Respon-
ders
Crying
time (min-
utes/d)
Adverse ef-
fects
Sethi 1988 26 26 Range 1 to
12
40 Sime-
thicone/
placebo
0 7 Ran-
domised,
cross-over
Frequency
of crying
(daily)
Am-
plitude of
crying at-
tack
Weissbluth
1984
48 48 5 58 Dicy-
clomine/
placebo
0 14 Ran-
domised,
parallel-
arm
Respon-
ders
Adverse ef-
fects
Weizman
1993
72 68 3.3 (1.2) 38.6 Herbal tea/
placebo
8.3/2.8 7 Ran-
domised,
parallel-
arm
Respon-
ders (as
colic elimi-
nated)
Frequency
of noctur-
nal awak-
enings
Colic im-
provement
score
*105 infants analysed for the three groups included in this review.
SD: standard deviation.
Table 2. Responders’ definitions
Author Responders’ definitions (as reported in the article) Notes on definitions (as considered in the review)
Akçam 2006 At each visit, parents described the effect of the last
treatment on a scale of 6: 0 = ’getting worse’, 1 =
’no improvement’, 2 = ’mild improvement’, 3 = ’mod-
-
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Table 2. Responders’ definitions (Continued)
erate improvement’ and 4 = ’completely well after
each dose’. Responders were infants with improve-
ment classified as 2, 3 or 4
Alexandrovich 2003 Relief of colic symptoms, which were defined as de-
crease in cumulative crying to < 9 hours/week
-
Alves 2012 Responses were classified as slightly improved, greatly
improved and completely improved
From the results, all included patients seemed to show
improvement. We considered as responders infants
who had “completely improved” - these infants had
colic cessation
Arikan 2008 N/A
Blomquist 1983 Parents’ ratings of the effects of infantile colic: excel-
lent, good, moderate, worsening
Data from diagram 2: We considered as responders
infants with excellent or good effects
Danielsson 1985 Number of infants with improvement in symptoms
(defined as better or much better)
-
Gomirato 1989 In the Methods section, improvement or worsening
of symptoms was classified as follows: - 2 crisis longer
than baseline (> 60 minutes); - 1 crisis longer than
baseline (within 30 to 60 minutes); 0 = no improve-
ment; + 1 crisis shorter than baseline (within 30 to 60
minutes); + 2 crisis shorter than baseline (> 60 min-
utes). In the Results section, only percentages of in-
fants with excellent, good, moderate or poor improve-
ment were reported
We considered as responders infants with excellent or
good improvement
Grunseit 1977 Pooled scoring symptoms (including postprandial cry-
ing, postprandial vomiting, sleeping disturbance); for
each symptom, 0 = no symptom, 1 = mild, 2 = mod-
erately severe, 3 = severe
-
Hwang 1985 Number of infants who improved receiving treatment
or placebo
-
Illingworth 1959 Results were graded from - 3 to + 3: + 1 the child was
slightly better, + 2 definitively better but still had some
discomfort, + 3 the infant was very greatly improved
and free from symptoms. - 1 the infant was slightly
worse
In the Results section, infants with + 3 seemed to be
considered as responders
Markestad 1997 Methods section: Parents described effects of the last
treatment on a scale from 5 ‘getting worse’ through
‘no improvement’, ‘some improvement’, ‘marked im-
provement’ and ‘complete stop of crying after each
dose’. Results section: No details on obtained effect
-
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Table 2. Responders’ definitions (Continued)
were provided - only the number of infants who re-
sponded to sucrose or to placebo
Metcalf 1994 A 5-point scale was used to identify the child’s symp-
toms as definitely better or symptom-free (+ 2), pos-
sibly better (+ 1), the same (0), possibly worse (- 1)
or definitely worse (- 2). Responders to simethicone
or to placebo were infants judged by the carer to have
had a positive response (+ 1, + 2) only to simethicone
or only to placebo
-
Montaseri 2013 N/A -
Savino 2002 Therapy was considered efficacious if crying ended
within 15 minutes after administration of com-
pounds. Responders were children who stopped cry-
ing within this time. The cutoff of 15 minutes was
derived from the minimal crying time of each crisis
before treatment
-
Savino 2005 Therapy was considered efficacious if crying time was
reduced by ≥ 50% per day; responders were infants
who had such a reduction in crying time
-
Sethi 1988 N/A -
Weissbluth 1984 Number of participants without colic. Colic was de-
fined on the basis of the Wessel definition (crying < 3
hours/d or crying > 3 hours/d for < 3 days/week)
-
Weizman 1993 Number of participants without colic. Colic was de-
fined on the basis of the Wessel definition (crying < 3
hours/d or crying > 3 hours/d for < 3 days/week)
-
N/A: not applicable, because this outcome was not assessed in the study.
Table 3. Results for adverse events
Study Experimen-
tal
treatment
Control Number of
partic-
ipants anal-
ysed (treat-
ment/
control)
Number of
ad-
verse events
in treat-
ment arm
Types of ad-
verse events
in treat-
ment arm
(number)
Number of
adverse
events in
control arm
Types of ad-
verse events
in
control arm
(number)
Notes
Akçam2006 Glucose
(30%)
Placebo 25/25 0 - 0 - No adverse
effect
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Table 3. Results for adverse events (Continued)
Alexan-
drovich
2003
Fennel (oil
emulsion)
Placebo 62/59 0 - 0 - No adverse
effect
Alves 2012 Simethicone Mentha 30/30 0 - 0 - No adverse
effect
Arikan 2008 Su-
crose (12%)
or herbal tea
(fennel)
No
treatment
35/35/35 UK - UK - -
Blomquist
1983
Dicy-
clomine plus
sugar
Placebo 18/18 UK - UK - -
Danielsson
1985
Simethicone Placebo 27/27 UK - UK - -
Gomirato
1989 Cimetropium
bromide 2.0
mg/kg
Cimetropium
bromide 1.2
mg/kg
20/20 4 Constipa-
tion (4)
0 - -
Grunseit
1977
Dicy-
clomine
Placebo 22/22 3 1 Con-
stipation (2)
, loose mo-
tions (1)
Constipa-
tion (1)
-
Hwang
1985
Dicy-
clomine
Placebo 30/30 4 Drowsy (4) 1 Drowsy (1) -
Illingworth
1959
Dicy-
clomine
Placebo 16/16 UK - UK - -
Markestad
1997
Sucrose
(12%)
Placebo 19/19 UK - UK - -
Metcalf
1994
Simethicone Placebo 83/83 UK - UK - -
Montaseri
2013
Fumaria ex-
tract
Placebo 26/24 UK - UK - -
Savino 2002
Cimetropium
bromide
Placebo 43/43 23 Me-
teorism (8);
vomiting (1)
; sleepiness
(7); inappe-
19 Meteorism
(12); sleepi-
ness (1)
; restlessness
-
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Table 3. Results for adverse events (Continued)
tence (1)
; cutaneous
reactions (3)
; constipa-
tion (3)
(1); consti-
pation (5)
Savino 2005 Herbal tea
(chamomile/
fennel/
balm-mint)
Placebo 41/47 16 Vomiting
(8); sleepi-
ness (2); in-
ap-
petence (1)
; cutaneous
reactions (1)
; constipa-
tion (4)
12 Vomiting
(2)
; sleepiness
(1); restless-
ness (1); in-
appetence
(3); consti-
pation (5)
-
Sethi 1988 Simethicone Placebo 26/26 0 - 0 - No adverse
effect
Weissbluth
1984
Dicy-
clomine
Placebo 24/24 2 Longer sleep
(1); wide-
eyed (1)
0 - -
Weizman
1993
Herbal tea
(chamomile/
vervain/
licorices/
fennel/
balm-mint)
Placebo 33/35 UK - UK - -
UK: unknown.
A P P E N D I C E S
Appendix 1. Record of searches
Record of searches up to 27 March 2015
Database Search date Issue or date Range of
database
Number of Records Limits
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(Continued)
Cochrane Central Reg-
ister of Controlled Tri-
als (CENTRAL) in the
Cochrane Library*
3 April 2012 2012, Issue 3 106 No limits
14 April 2014 2014, Issue 3 4 2012-2014
27 March 2015 2015, Issue 2 3 2014-2015
16 May 2016 2016, Issue 4 3 2015-2016
Ovid MEDLINE (R) 3 April 2012 1946 to March week 3
2012
190 No limits
11 April 2014 1946 to April week 1
2014
4 ed=2012041-20140411
27 March 2015 1946 to March week 4
2015
4 ed=20140401-
20150319
16 May 2016 1946 to May week 1
2016
3 ed=20150319-
20160505
Ovid Medline In-Pro-
cess & Other Non-In-
dexed Citations
27 March 2015 26 March 2015 6 No limits
16 May 2016 13 May 2016 6 No limits
Embase Ovid 3 April 2012 1980 to 2012 week 13 292 No limits
11 April 2014 1980 to 2014 week 14 11 em=201213-201414
27 March 2015 1980 to 2015 week 12 8 em=201414-201512
16 May 2016 1980 to 2016 week 20 10 em=201512 -201619
PsycINFO Ovid 3 April 2012 1967 to March week 3
2012
31 No limits
11 April 2014 1806 to April week 2
2014
3 up=20120402-
20140407
27 March 2015 1806 to March week 4
2015
1 up=20140407-
20150323
16 May 2016 1806 to May week 2
2016
3 up=20150330-
20160509
CINAHL EBSCO (Cu-
mulative Index to Nurs-
ing and Allied Health
Literature)
3 April 2012 1937 to current 36 No limits
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(Continued)
14 April 2014 1937 to current 6 EM 20120401-
27 March 2015 1937 to current 5 EM 20140401-
16 May 2016 1937 to current 5 EM 20150301-
Science Citation Index
Web of Science (SCI)
3 April 2012 1970 to 30 March 2012 242 No limits
Social Science Citation
Index Web of Science
(SSCI)
3 April 2012 1970 to 30 March 2012 15 No limits
Science Citation Index
(SCI) & Social Science
Citation Index (SSCI)
14 April 2014 1970 to 11 April 2014 12 2012 -2014
27 March 2015 1970 to 26 March 2015 6 2014-2015
17 May 2016 1970 to 16 May 2016 5 2015-2016
Conference Proceedings
Citation Index - Science
Web of Science (CPCI-
S);
Conference Proceedings
Citation Index - Social
Sciences & Humanities
Web of Science (CPCI-
SS&H)
03 April 2012 1990 to 30 March 2012 0 No limits
14 April 2014 1990 to 11 April 2014 0 2012-2014
27 March 2015 1990 to 26 March 2015 0 2014-2015
17 May 2016 1970 to 16 May 2016 0 2015-2016
CochraneDatabase of Sys-
tematic Reviews (CDSR)
in the Cochrane Library
03 April 2012 2012 Issue 3 26 No limits
14 April 2014 2014 Issue 4 0 2012-2014
27 March 2015 2015 Issue 3 0 2014-2015
16 May 2016 2016 Issue 5 0 2015-2016
Database of Abstracts
of Reviews of Effec-
tiveness (DARE) in the
Cochrane Library
3 April 2012 2012 Issue 1 20 No limits
14 April 2014 2014 Issue 1 0 2012-2014
27 March 2015 2015 issue 1 0 2014-2015
16 May 2016 2016 Issue 2 0 2015-2016
WorldCat (
worldcat.org)
4 April 2012 All available years 2 Limited to theses
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(Continued)
14 April 2014 All available years 1 Limited to theses; 2012-
2014
27 March 2015 All available years 1 Limited to theses; 2014-
2015
17 May 2016 all available years 0 Limited to theses; 2015-
2016
HOMEOINDEX
(VHL; bvsalud.org/en)
02 April 2012 All available years 27 No limits
14 April 2014 All available years 1 Compared with previous
records
27 March 2015 All available years 0 Compared with previous
records
17 May 2016 all available years 3 2015-2016
LILACS (VHL;
lilacs.bvsalud.org/en)
2 April 2012 All available years 17 No limits
15 April 2014 All available years 0 2012-2014
27 March 2015 All available years 0 2014-2015
17 May 2016 All available years 2 2015-2016
Networked Digital Li-
brary of
Theses and Dissertations
SCIRUS (NDLTD)
3 April 2012 All available years 20 Email attachment
15 April 2014 No longer available No longer available No longer available
Networked Digital Li-
brary of Theses and Dis-
sertations (NDLTD) (
search.ndltd.org/
index.php)
17 May 2016 All available years 1 -
IBECS (VHL;
bvsalud.org/en)
02 April 2012 All available years 7 No limits
15 April 2014 All available years 0 2012-2014
27 March 2015 All available years 7 2014-2015
17 May 2016 All available years 2 2015-2016
ClinicalTrials.gov (
clinicaltrials.gov)
3 April 2012 All available years 18 No limits
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(Continued)
15 April 2014 All available years 19 Trials received from 04/
01/2012 to 04/15/2014
27 March 2015 All available years 0 Trials received from 04/
01/2014 to 03/27/2015
17 May 2016 All available years 11 Trials received from 03/
01/2015 to 05/17/2015
World Health Organiza-
tion International Clini-
cal Tri-
als Registry (WHO IC-
TRP; apps.who.int/
trialsearch)
03 April 2012 All available years 43 No limits
15 April 2014 All available years 15 Trials registered from04/
01/2012 to 04/15/2014
27 March 2015 All available years 21 Trials registered in 2014
or 2015
17 May 2016 all available years 22 Trials registered in 2015
or 2016
Australasian Theses
(TROVE;
trove.nla.gov.au)
3 April 2012 All available years 0 No records
15 April 2014 All available years 0 No records
27 March 2015 All available years 0 No records
Not searched as not pro-
ductive
Not searched as not pro-
ductive
Not searched as not pro-
ductive
Not searched as not pro-
ductive
DART-Europe E-
theses Portal (www.dart-
europe.eu/basic-
search.php)
3 April 2012 All available years 0 No records
15 April 2014 All available years 0 No records
27 March 2015 All available years 0 No records
Not searched as not pro-
ductive
Not searched as not pro-
ductive
Not searched as not pro-
ductive
Not searched as not pro-
ductive
Total number of records 1230
*includes the Cochrane Developmental, Psychosocial and Learning Problems Group Specialised Register.
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Appendix 2. Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, which includes the
Cochrane Developmental, Psychosocial and Learning Problems Group Specialised Register
CENTRAL strategy used for 2012 searches
#1MeSH descriptor Crying, this term only
#2MeSH descriptor Colic, this term only
#3cry or crying or cries
#4colic*
#5((stomach or abdominal or abdomen*) NEAR/3 (spasm* or pain* or cramp*)) in Cochrane Reviews and Other Reviews
#6((gastric or gastro*) NEAR/3 (spasm* or pain* or cramp*))
#7(#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8MeSH descriptor Dicyclomine, this term only
#9MeSH descriptor Simethicone, this term only
#10Dic*clomine
#11simethicon*
#12cimetropium*
#13bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol
#14MeSH descriptor Plant Extracts, this term only
#15MeSH descriptor Plants, Medicinal, this term only
#16MeSH descriptor Phytotherapy, this term only
#17phytotherap*
#18(herbal NEAR/3 (agent* or formulation* or medicine* or remed*))
#19plant extract*
#20MeSH descriptor Chamomile explode all trees
#21chamomile OR camomile
#22MeSH descriptor Melissa, this term only
#23(lemonbalm or lemon-balm or melissa*)
#24MeSH descriptor Foeniculum, this term only
#25Foeniculum*
#26fennel
#27(#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
OR #23 OR #24 OR #25 OR #26)
#28(#7 AND #27)
CENTRAL strategy with age filter used for searches 2014 onwards
#1MeSH descriptor: [Crying] this term only
#2MeSH descriptor: [Colic] this term only
#3(cry or crying or cries)
#4colic*
#5((stomach or abdominal or abdomen*) near/3 (spasm* or pain* or cramp*))
#6((gastric or gastro*) near/3 (spasm* or pain* or cramp*))
#7#1 or #2 or #3 or #4 or #5 or #6
#8MeSH descriptor: [Infant] 1 tree(s) exploded
#9(infant* or baby or babies or child* or neonat* or p*ediatric*)
#10#8 or #9
#11#7 and #10
#12MeSH descriptor: [Dicyclomine] this term only
#13MeSH descriptor: [Simethicone] this term only
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#14Dic*clomine
#15simethicon*
#16cimetropium*
#17bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol
#18MeSH descriptor: [Plant Extracts] this term only
#19MeSH descriptor: [Plants, Medicinal] this term only
#20MeSH descriptor: [Phytotherapy] this term only
#21phytotherap*
#22(herbal near/3 (agent* or formulation* or medicine* or remed*))
#23plant extract* 4105
#24MeSH descriptor: [Chamomile] explode all trees
#25chamomile or camomile
#26MeSH descriptor: [Melissa] this term only
#27(lemonbalm or lemon-balm or melissa*)
#28MeSH descriptor: [Foeniculum] this term only
#29Foeniculum*
#30fennel
#31#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or
#30
#32#11 and #31
Ovid MEDLINE (R)
Ovid MEDLINE strategy used for 2012 searches
1 crying/ (1886)
2 (cry or crying or cries).tw.
3 colic/
4 colic$.tw.
5 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
7 or/1-6
8 dicyclomine/
9 Dic#clomine.tw.
10 simethicone/
11 simethicon$.tw.
12 cimetropium$.tw.
13 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or “spascol”).tw.
14 Herbal medicine/
15 Plant extracts/
16 Plants,medicinal/
17 Phytotherapy/
18 phytot?erap$.tw.
19 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
20 plant extract$.tw.
21 exp Chamomile/
22 c?amomile.tw.
23 Melissa/
24 (lemonbalm or lemon-balm or melissa$).tw.
25 Foeniculum/
26 Foeniculum$.tw.
27 fennel.tw.
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28 or/8-27
29 randomized controlled trial.pt.
30 controlled clinical trial.pt.
31 randomi#ed.ab.
32 placebo$.ab.
33 drug therapy.fs.
34 randomly.ab.
35 trial.ab.
36 groups.ab.
37 or/29-36
38 exp animals/ not humans.sh.
39 37 not 38
40 7 and 28 and 39
Lines 29 to 39 comprise the sensitivity-maximising version of the Cochrane Highly Sensitive Search Strategy for identifying randomized
trials in MEDLINE (Lefebvre 2008)
Ovid MEDLINE strategy limited to infant age group used for searches 2014 onwards
1 crying/
2 (cry or crying or cries).tw.
3 colic/
4 colic$.tw.
5 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
7 or/1-6
8 exp infant/
9 (baby or babies or child$ or infant$ or newborn$ or neonat$).tw.
10 or/8-9
11 7 and 10
12 dicyclomine/
13 Dic#clomine.tw.
14 simethicone/
15 simethicon$.tw.
16 cimetropium$.tw.
17 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl or spascol”).tw.
18 Herbal medicine/
19 Plant extracts/
20 Plants,medicinal/
21 Phytotherapy/
22 phytot?erap$.tw.
23 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
24 plant extract$.tw.
25 exp Chamomile/
26 c?amomile.tw.
27 Melissa/
28 (lemonbalm or lemon-balm or melissa$).tw.
29 Foeniculum/
30 Foeniculum$.tw.
31 fennel.tw.
32 or/12-31
33 randomized controlled trial.pt.
34 controlled clinical trial.pt.
35 randomi#ed.ab.
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36 placebo$.ab.
37 drug therapy.fs.
38 randomly.ab.
39 trial.ab.
40 groups.ab.
41 or/33-40
42 exp animals/ not humans.sh.
43 41 not 42
44 11 and 32 and 43
Lines 33 to 43 comprise the sensitivity-maximising version of the Cochrane Highly Sensitive Search Strategy for identifying randomized
trials in MEDLINE (Lefebvre 2008).
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Ovid MEDLINE In-Process strategy used for 2015 searches
1 (cry or crying or cries).tw.
2 colic$.tw.
3 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
4 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 (baby or babies or child$ or infant$ or newborn$ or neonat$).tw.
6 Dic#clomine.tw.
7 simethicon$.tw.
8 cimetropium$.tw.
9 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl or spascol”).tw.
10 phytot?erap$.tw. (154)
11 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
12 plant extract$.tw.
13 c?amomile.tw.
14 (lemonbalm or lemon-balm or melissa$).tw.
15 Foeniculum$.tw.
16 fennel.tw.
17 or/1-4
18 5 and 17
19 or/6-16
20 18 and 19
Embase Ovid
Embase strategy used for 2012 searches.
1 crying/
2 (cry or crying or cries).tw.
3 colic/
4 colic$.tw.
5 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
7 or/1-6
8 dicycloverine/
9 simethicone/
10 Dic#clomine.tw.
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11 simethicon$.tw.
12 cimetropium$.tw.
13 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol).tw.
14 herbal medicine/
15 plant extract/
16 medicinal plant/
17 phytotherapy/
18 phytot?erap$.tw.
19 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
20 plant extract$.tw.
21 chamomile/
22 digestive tract agent/
23 c?amomile.tw.
24 Melissa officinalis/
25 (lemonbalm or lemon-balm or melissa$).tw.
26 fennel/
27 Foeniculum/
28 Foeniculum$.tw.
29 fennel oil/
30 fennel.tw.
31 or/8-30
32 exp Clinical trial/
33 Randomized controlled trial/
34 Randomization/
35 Single blind procedure/
36 Double blind procedure/
37 Crossover procedure/
38 Placebo/
39 Randomi#ed.tw.
40 RCT.tw.
41 (random$ adj3 (allocat$ or assign$)).tw.
42 randomly.ab.
43 groups.ab.
44 trial.ab.
45 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
46 Placebo$.tw.
47 Prospective study/
48 (crossover or cross-over).tw.
49 prospective.tw.
50 or/32-49
51 7 and 31
52 50 and 51
Embase strategy limited to infant age group used for searches 2014 onwards.
1 crying/
2 (cry or crying or cries).tw.
3 colic/
4 colic$.tw.
5 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
7 or/1-6
8 exp infant/
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9 (baby or babies or child$ or infant$ or newborn$ or neonat$).tw.
10 or/8-9
11 7 and 10
12 dicycloverine/
13 simethicone/
14 Dic#clomine.tw.
15 simethicon$.tw.
16 cimetropium$.tw.
17 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol).tw.
18 herbal medicine/
19 plant extract/
20 medicinal plant/
21 phytotherapy/
22 phytot?erap$.tw.
23 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
24 plant extract$.tw.
25 chamomile/
26 digestive tract agent/
27 c?amomile.tw.
28 Melissa officinalis/
29 (lemonbalm or lemon-balm or melissa$).tw.
30 fennel/
31 Foeniculum/
32 Foeniculum$.tw.
33 fennel oil/
34 fennel.tw.
35 or/12-34
36 exp Clinical trial/
37 Randomized controlled trial/
38 Randomization/
39 Single blind procedure/
40 Double blind procedure/
41 Crossover procedure/
42 Placebo/
43 Randomi#ed.tw.
44 RCT.tw. (13384)
45 (random$ adj3 (allocat$ or assign$)).tw.
46 randomly.ab.
47 groups.ab.
48 trial.ab.
49 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
50 Placebo$.tw.
51 Prospective study/
52 (crossover or cross-over).tw.
53 prospective.tw.
54 or/36-53
55 11 and 35 and 54
PsycINFO Ovid
1 exp Crying/
2 (cry or crying or cries).tw.
3 colic$.tw.
96Pain-relieving agents for infantile colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 or/1-5
7 Dic#clomine.tw.
8 simethicon$.tw.
9 cimetropium$.tw.
10 (bentyl$ or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol).tw.
11 “medicinal herbs and plants”/
12 “plants (botanical)”/
13 folk medicine/
14 alternative medicine/
15 phytot?erap$.tw.
16 (herbal adj3 (agent$ or formulation$ or medicine$ or remed$)).tw.
17 plant extract$.tw.
18 c?amomile.tw.
19 (lemonbalm or lemon-balm or melissa$).tw.
20 Foeniculum$.tw.
21 fennel.tw.
22 or/7-21
23 6 and 22
CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature)
S42 S27 and S41
S41 S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40
S40 placebo*
S39 crossover* or “cross over*”
S38 (MH “Crossover Design”)
S37 (tripl* N3 mask*) or (tripl* N3 blind*)
S36 (trebl* N3 mask*) or (trebl* N3 blind*)
S35 (doubl* N3 mask*) or (doubl* N3 blind*)
S34 (singl* N3 mask*) or (singl* N3 blind*)
S33 (clinic* N3 trial*) or (control* N3 trial*)
S32 (random* N3 allocat* ) or (random* N3 assign*)
S31 randomis* or randomiz*
S30 (MH “Meta Analysis”)
S29 (MH “Clinical Trials+”)
S28 MH random assignment 5
S27 S7 and S26
S26 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25
S25 Foeniculum* or fennel*
S24 (MH “Fennel”) S
S23 (lemonbalm or lemon-balm or melissa*)
S22 (MH “Lemon Balm”) S
S21 c#amomile
S20 (MH “Chamomile”)
S19 plant extract* S
S18 (herbal N3 (agent* or formulation* or medicine* or remed*))
S17 phytotherap*
S16 (MH “Medicine, Herbal”)
S15 (MH “Plants, Medicinal”)
S14 (MH “Plant Extracts”)
S13 (bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol)
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S12 cimetropium*
S11 simethicon*
S10 (MH “Simethicone”)
S9 Dic?clomine
S8 (MH “Dicyclomine”)
S7 S1 or S2 or S3 or S4 or S5 or S6
S6 ((gastric or gastro*) N3 (spasm* or pain* or cramp*))
S5 ((stomach or abdominal or abdomen*) N3 (spasm* or pain* or cramp*))
S4 colic*
S3 (cry or crying or cries)
S2 (MH “Crying”)
S1 (MH “Infant Colic”)
Web of Science databases
Science Citation Index (SCI)
Social Science Citation Index (SSCI)
Conference Proceedings Citation Index - Science (CPCI-S)
Conference Proceedings Citation Index - Social Sciences & Humanities (CPCI-SS&H)
#11#10 AND #4
DocType=All document types; Language=All languages;
#10#9 OR #8 OR #7 OR #6 OR #5
DocType=All document types; Language=All languages;
#9TS= (chamomile Or camomile OR Melissa OR lemonbalm or lemon-balm OR melissa* OR Foeniculum* OR fennel*)
DocType=All document types; Language=All languages;
#8TS= (herbal NEAR/3 (agent* or formulation* or medicine* or remed*))
DocType=All document types; Language=All languages;
#7TS=phytotherap*
DocType=All document types; Language=All languages;
#6TS=(plant* NEAR/3 (extract* OR medicinal))
DocType=All document types; Language=All languages;
#5TS=(dicyclomin* OR simethicon* OR cimetropium* OR bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin
or di-spaz or florizel or lomine or “or-tyl” or spascol)
DocType=All document types; Language=All languages;
#4#3 OR #2 OR #1
DocType=All document types; Language=All languages;
#3TS= ((gastric or gastro*) NEAR/3 (spasm* or pain* or cramp*))
DocType=All document types; Language=All languages;
#2TS= ((stomach or abdominal or abdomen*) NEAR/3 (spasm* or pain* or cramp*))
DocType=All document types; Language=All languages;
#1TS=(cry or crying or cries or colic*)
DocType=All document types; Language=All languages;
Cochrane Database of Systematic Reviews (CDSR) in the Cochrane Library
#1MeSH descriptor: [Crying] this term only
#2MeSH descriptor: [Colic] this term only
#3(cry or crying or cries):ti,ab
#4colic*
#5((stomach or abdominal or abdomen*) near/3 (spasm* or pain* or cramp*)):ti,ab
#6((gastric or gastro*) near/3 (spasm* or pain* or cramp*)):ti,ab
#7#1 or #2 or #3 or #4 or #5 or #6
#8MeSH descriptor: [Infant] 1 tree(s) exploded
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#9(infant* or baby or babies or child* or neonat* or p*ediatric*):ti,ab
#10#8 or #9
#11#7 and #10
#12MeSH descriptor: [Dicyclomine] this term only
#13MeSH descriptor: [Simethicone] this term only
#14Dic*clomine:ti,ab
#15simethicon*:ti,ab
#16cimetropium*:ti,ab
#17(bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol):
ti,ab
#18MeSH descriptor: [Plant Extracts] this term only
#19MeSH descriptor: [Plants, Medicinal] this term only
#20MeSH descriptor: [Phytotherapy] this term only
#21phytotherap*:ti,ab
#22(herbal near/3 (agent* or formulation* or medicine* or remed*)):ti,ab
#23plant next extract*:ti,ab
#24MeSH descriptor: [Chamomile] explode all trees
#25(chamomile or camomile):ti,ab
#26MeSH descriptor: [Melissa] this term only
#27(lemonbalm or lemon-balm or melissa*):ti,ab
#28MeSH descriptor: [Foeniculum] this term only
#29Foeniculum*:ti,ab
#30fennel:ti,ab
#31#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or
#30
#32#11 and #31
Database of Abstracts of Reviews of Effects (DARE) in the Cochrane Library
#1MeSH descriptor: [Crying] this term only
#2MeSH descriptor: [Colic] this term only
#3(cry or crying or cries):ti,ab
#4colic*
#5((stomach or abdominal or abdomen*) near/3 (spasm* or pain* or cramp*)):ti,ab
#6((gastric or gastro*) near/3 (spasm* or pain* or cramp*)):ti,ab
#7#1 or #2 or #3 or #4 or #5 or #6
#8MeSH descriptor: [Infant] 1 tree(s) exploded
#9(infant* or baby or babies or child* or neonat* or p*ediatric*):ti,ab
#10#8 or #9
#11#7 and #10
#12MeSH descriptor: [Dicyclomine] this term only
#13MeSH descriptor: [Simethicone] this term only
#14Dic*clomine:ti,ab
#15simethicon*:ti,ab
#16cimetropium*:ti,ab
#17(bentyl* or bentylol or merbentyl or di-cyclonex or dibent or dicycloverin or di-spaz or florizel or lomine or “or-tyl” or spascol):
ti,ab
#18MeSH descriptor: [Plant Extracts] this term only
#19MeSH descriptor: [Plants, Medicinal] this term only
#20MeSH descriptor: [Phytotherapy] this term only
#21phytotherap*:ti,ab
#22(herbal near/3 (agent* or formulation* or medicine* or remed*)):ti,ab
#23plant next extract*:ti,ab
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#24MeSH descriptor: [Chamomile] explode all trees
#25(chamomile or camomile):ti,ab
#26MeSH descriptor: [Melissa] this term only
#27(lemonbalm or lemon-balm or melissa*):ti,ab
#28MeSH descriptor: [Foeniculum] this term only
#29Foeniculum*:ti,ab
#30fennel:ti,ab
#31#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or
#30
WorldCat
su:infant colicLimited to theses/dissertations
HomeoIndex (Virtual Health Library)
(“COLIC” or “CRYING”) [Subject descriptor] or colic$ or cry$ or cries [Words]
LILACS (Virtual Health Library)
tw:(colic* OR cries OR crying )) OR (mh:(“colic”)) OR (mh:(“crying”)) AND ( db:(“LILACS”) AND type˙of˙study:(“clinical˙trials”))
Networked Digital Library of Theses and Disserations SCIRUS (NDLTD)
Not searched after 2012 because SCIRUS no longer functioning.
“infant colic” and random*
Networked Digital Library of Theses and Disserations (NDLTD)
(search.ndltd.org/index.php)
“infant colic” and random*
IBECS (Virtual Health Library)
(tw:(colic* OR cries OR crying OR cry)) OR (mh:( “colic” OR “crying” )) AND (instance:“regional”) AND ( db:(“IBECS”) AND
type˙of˙study:(“clinical˙trials”))
ClinicalTrials.gov
Advanced search: Condition= infant colic AND Study type= intervention
World Health Organisation International Clinical Trials Registry Platform (WHO ICTRP)
Basic search: infant AND crying OR infant AND cries OR infant AND colic
TROVE
KEYWORD This phrase: infant colic and KEYWORD random*
DART-Europe E-theses Portal
“infant colic” and random*
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Appendix 3. Criteria for judging risk of bias
Item Judgement Description
Random sequence generation (selection
bias)
Low risk Investigators describe a random component in the sequence generation
process such as random numbers table; computer random number gen-
erator; coin tossing; shuffling cards or envelopes; throwing dice; drawing
of lots; minimisation
High risk Investigators describe a non-random component in the sequence genera-
tion process such as odd or even date of birth; date (or day) of admission;
hospital or clinic record number; alternation; judgement of the clinician;
results of a laboratory test or a series of tests; availability of the interven-
tion
Unclear risk Information about the sequence generation process was insufficient to
permit judgement of low or high risk
Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal al-
location: central allocation (including telephone, web-based and phar-
macy-controlled randomisation); sequentially numbered drug containers
of identical appearance; sequentially numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. envelopes were unsealed or were non-opaque
or were not sequentially numbered); alternation or rotation; date of birth;
case record number; any other explicitly unconcealed procedure
Unclear risk Information was insufficient to permit judgement of low or high risk.
This is usually the case if the method of concealment is not described or
is not described in sufficient detail to allow a definitive judgement
Blinding of participants and personnel
(performance bias)
Low risk No blinding or incomplete blinding, but review authors judge that the
outcome is not likely to be influenced by lack of blinding; or blinding of
participants and key study personnel ensured, and unlikely that blinding
could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that blinding could have been broken,
and the outcome is likely to be influenced by lack of blinding
Unclear risk Information was insufficient to permit judgement of low or high risk
Blinding of outcome assessment (detection
bias) - objective outcomes
Low risk No blinding of outcome assessment, but review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
or blinding of outcome assessment ensured and unlikely that blinding
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(Continued)
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding; or blinding of outcome assess-
ment, but likely that blinding could have been broken and the outcome
measurement is likely to be influenced by lack of blinding
Unclear risk Information was insufficient to permit judgement of low or high risk
Incomplete outcome data (attrition bias).
For all outcomes except retention in treat-
ment or dropout
Low risk No missing outcome data; or percentage of missing data ≤ 10% of the
overall sample and (1) reasons for missing outcome data unlikely to be
related to true outcome (for survival data, censoring unlikely to be in-
troducing bias), (2) missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data across groups,
(3) for dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically rele-
vant impact on the intervention effect estimate and (4) for continuous
outcome data, plausible effect size (difference in means or standardised
difference in means) among missing outcomes not enough to have a clin-
ically relevant impact on observed effect size; or missing data > 10% but
(1) they have been imputed using appropriate methods, or (2) all ran-
domised participants are reported/analysed in the group to which they
were allocated by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Percentage of missing data > 10% or missing data unbalanced across
groups; or reason for missing outcome data likely to be related to true
outcome, with imbalance in numbers or reasons for missing data across
intervention groups; or, for dichotomous outcome data, the proportion
ofmissing outcomes comparedwith observed event risk enough to induce
clinically relevant bias in intervention effect estimate; or, for continuous
outcome data, plausible effect size (difference in means or standardised
difference inmeans) amongmissing outcomes enough to induce clinically
relevant bias in observed effect size; or
‘as-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Information insufficient to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of dropouts not reported for each group)
Selective outcome reporting (reporting
bias)
Low risk The study protocol is available, and all of the study’s prespecified (primary
and secondary) outcomes that are of interest in the review have been
reported in the prespecified way; or the study protocol is not available
but all study outcomes declared in the Methods section were reported in
the Results
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(Continued)
High risk Not all of the study’s prespecified primary outcomes have been reported;
or ≥ 1 primary outcome is reported using measurements, analysis meth-
ods or subsets of the data (e.g. subscales) that were not prespecified; or≥ 1
reported primary outcome was not prespecified (unless clear justification
for their reporting is provided, such as an unexpected adverse effect); or
≥ 1 outcome of interest in the review is reported incompletely, so cannot
be entered into a meta-analysis; or the study report fails to include results
for a key outcome that would be expected to have been reported for such
a study
Unclear risk Information insufficient to permit judgement of low or high risk
Other bias Low risk The study appeared to be free of other sources of bias such as being stopped
early because of a data-dependent process or having a baseline imbalance
between groups. For cross-over studies, we assessed if a washout period
≥ 1 day was provided
High risk Baseline imbalance among groups; or no washout period for cross-over
studies
Unclear risk Information insufficient to permit judgement of low or high risk; study
authors contacted for clarification, but the information was not forth-
coming
Appendix 4. Methods reported in the protocol and not used in the review
Analysis Method
Dealing with missing data For studies missing > 40% of their data, we intended to conduct sensitivity
analysis to explore the nature of the missing data, when available data
permitted
Subgroup analysis and investigation of heterogeneity We planned to conduct the following subgroup analyses:
• Age of mother at time of birth (younger vs older; i.e. 21 years of
age and under vs over 21 years of age);
• Type of feeding (bottle fed vs breast fed);
• Atopy (lower vs higher risk of atopy);
• Short-term and long-term follow-up (< 4 weeks of treatment vs ≥
4 weeks of treatment); and
• Low-quality trials versus high-quality trials (allocation concealment
vs lack of allocation concealment; blinding vs lack of blinding) (Savino
2012).
These analyses would have been exploratory as they involved non-exper-
imental (cross-study) comparisons, and given the large numbers of sub-
group analyses, they may lead to misleading conclusions (Yusuf 1991;
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(Continued)
Oxman 1992).
Sensitivity analysis We planned to assess the sensitivity of findings for any imputed data to
explore the possible impact of missing data (Savino 2012).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have partially modified the Methods section, as explained below.
First, in the Types of interventions subsection, we added the example of “sucrose or glucose”.
Second, in the Types of outcome measures subsection, we:
• replaced point 2 (worsening of symptoms) with “Responders”, under Primary outcomes, because we noted that most studies
evaluated symptoms as the percentage of infants with improvement, not with deterioration (i.e. worsening);
• modified the outcome “Reduction in frequency of crying episodes (post-treatment vs baseline)*”, under Secondary outcomes,
from “dichotomous” to “data available may be continuous, for example, hours per day, or dichotomous, for example, reduction under
a threshold defined by trialists”; and
• removed “Presence/absence of colic after treatment” from our list of Secondary outcomes because it was already captured by the
outcome “Numbers of responders”.
Third, in the Searching other resources subsection, we deleted the sentences on searching Google and Google Scholar, as these searches
were not performed.
Fourth, in the Assessment of risk of bias in included studies subsection, we moved to Appendix 3 our description of how we assessed
each study for risk of bias across each of the seven domains.
Fifth, in the Unit of analysis issues subsection, under the heading ”Cross-over studies“, we added details on the method used to analyse
cross-over studies. This section now reads as follows: ”We used the inverse variance method, as recommended by Elbourne 2002, to
include data from cross-over studies with an adequate washout period. To take account of the correlation between the two study periods,
we calculated the correlation co-efficient between periods for each study (Savino 2012). When the correlation co-efficient could not be
obtained, we used data from the first period only. For continuous data, no studies reported the SD of a paired t-test, and for binary data,
only one of the included studies with a planned washout period reported the number of participants who responded to both treatments
(Metcalf 1994). Consequently, we decided to analyse cross-over trials as if they were parallel-group trials. This approach, even if it is
not the most correct, is conservative, as it overestimates the variability between study periods. Furthermore, we conducted separate
meta-analyses for cross-over and parallel-group trials, thus avoiding the unit of analysis error. For cross-over studies with an inadequate
washout period, we used data from the first period only. If data from the first period were not available, we did not incorporate these
studies into a meta-analysis.“
Sixth, in the Assessment of heterogeneity section, we added that we ”used Tau² to assess between-study variability“.
Finally, we added the following paragraph to a new subsection entitled, ”Summary of findings table“, beneath the Data synthesis
subsection:
”We summarised the evidence in ’Summary of findings’ tables and provided summary estimates of absolute and relative effects (see
Summary of findings table 1; Summary of findings table 2; Summary of findings table 3; and Summary of findings table 4). We in-
cluded a rating (ranging from very low to high) of our confidence in the estimate of effect for the overall quality of evidence for each
outcome as assessed via the GRADE approach (Guyatt 2008; Guyatt 2013).We used an iterative, electronic correspondence discussion
process to reach consensus on factors that affect confidence in the estimate of effects, including risk of bias (i.e. design and study
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limitations), imprecision, indirectness (directness in the GRADE approach includes generalisability and applicability), inconsistency
of results (i.e. heterogeneity), magnitude of effect and issues of residual plausible confounding; and in evidence rating.“
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